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Abstract 
 
The incidence of obesity increased rapidly in the developed countries during the last decades. 
Obesity has high impact on the population health and also on the health care cost. Therefore, 
understanding the regulatory mechanisms of the energy homeostasis has critical importance. 
The goal of our studies was to better understand the regulation of the energy homeostasis by 
hypothalamic circuits. The hypothalamic paraventricular nucleus (PVN) is an important 
hypothalamic centre in the regulation of the energy homeostasis. Using electron microscopy, 
we demonstrated that the nitric oxide (NO) system is anatomically positioned to be utilized as 
both anterograde and retrograde transmitter system in the PVN. The association of the NO 
synthesizing enzyme, the neuronal nitric oxide synthase (nNOS), to the postsynaptic side of 
synapses formed by type 1 cannabinoid receptor (CB1)-containing axons in the parvocellular 
part of the PVN suggests that the NO and the endocannabinoid systems may interact in the 
regulation of presynaptic terminals of parvocellular neurons. Our in vivo studies revealed that 
both the NO and the endocannabinoid systems of the PVN are involved in the regulation of the 
energy homeostasis by neuropeptide Y (NPY) an orexigenic peptide of the hypothalamic 
arcuate nucleus (ARC). While inhibition of the NO system inhibits the effects of NPY on the 
food intake, inhibition of CB1 in the PVN markedly decreases the effect of NPY on the energy 
expenditure. The hypophysiotropic thyrotropin-releasing hormone (TRH)-synthesizing 
neurons of the PVN play important role in the regulation of energy expenditure by controlling 
the hormone synthesis of the thyroid gland. We demonstrated that the axon terminals of these 
neurons contain the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) in the 
external zone of the median eminence (ME) where these terminals are closely associated with 
tanycytes, the cell type that expresses the thyroid hormone activating type 2 deiodinase 
suggesting that the TRH neurons accumulate the active thyroid hormone, T3, from the ME 
where T3 originates from the blood and from tanycytes. 
The non-hypophysiotropic TRH neurons in the perifornical area/BNST region express a 
second anorexigenic peptide, the urocortin 3 (UCN3). We showed that these TRH/UCN3 
neurons form symmetric type synaptic associations with the anorexigenic POMC neurons of 
the ARC raising the possibility that the TRH/UCN3 neurons regulate the food intake via the 
POMC neurons of the ARC. 
In addition, we demonstrated that TRH-containing axons densely innervate the histaminergic 
neurons in all subnuclei of the tuberomammillary nucleus indicating that the histaminergic 
neurons may receive feeding related inputs from non-hypophysiotropic TRH populations.  
DOI:10.15774/PPKE.ITK.2018.001
3 
 
Acknowledgements 
 
Firstly, I would like to thank my scientific advisor Csaba Fekete for his guidance, patience 
and valuable support during my studies.  
 
I am also grateful to Balázs Gereben, Imre Farkas and Zsolt Liposits for their help in my 
studies. 
 
I thank my former and current colleagues Anett Szilvásy-Szabó, Andrea Kádár, Ágnes 
Simon, Andrea Juhász, Anikó Zeöld, Barbara Vida, Csaba Vastagh, Csilla Molnár, Enikő 
Kiss, Erik Hrabovszky, Flóra Bálint, Györgyi Zséli, Imre Kalló, Judit Szabon, Kata Skrapits, 
Mónika Tóth, Petra Mohácsik, Vera Maruzs, Zoltán Péterfi, Zsuzsa Beliczai and Zsuzsa 
Bardóczi. 
 
I would also like to acknowledge the very important contribution of the co-authors of our 
papers Anna Sárvári, Gábor Wittmann, Kata Nagyunyomi-Sényi, László Barna, Masahiko 
Watanabe, Motokazu Uchigashima, Miklós Palkovits, Raphaël G. P. Denis, Ronald M. 
Lechan, Serge Luquet, Tamás Füzesi, Ann Marie Zavacki, Rafael Arrojo e Drigo, Liping 
Dong, Beáta A. Borsay, László Herczeg, Antonio C. Bianco.  
 
Furthermore, I am thankful to the Doctoral School; especially to Prof. Péter Szolgay for the 
opportunity to participate in the doctoral program. I thank Katinka Tivadarné Vida for her 
always kind help and patience to make the administrative side of life easier.  
 
I am very grateful to my mother and my friends who always believed in me and supported me. 
Finally, I am especially appreciated my husband András for all his love, patience, support 
and encouragement that gave me the strength to go on even in the hardest periods of this 
journey. 
  
DOI:10.15774/PPKE.ITK.2018.001
4 
 
List of abbreviations 
 
2-AG   – 2-arachidonoylglycerol 
AGRP  – agouti-related neuropeptide 
ARC   – arcuate nucleus 
BAT   – brown adipose tissue 
BBB   – blood-brain-barrier 
BNST  – bed nucleus of stria terminalis 
cAMP   – cyclic adenosine monophosphate 
CART   – cocaine- and amphetamine-regulated transcript 
CB1   – type 1 cannabinoid receptor  
CCK   – cholecystocinin 
CNS   – central nervous system 
CRFR2   – corticotropin-releasing factor receptor 2 
CRH   – corticotropin-releasing hormone 
CSF  – cerebrospinal fluid 
D2   – deiodinase 2 
DAB   – diaminobenzidine 
DAGLα  – diacylglycerol lipase alpha 
DMN   – dorsomedial nucleus 
eNOS   – endothelial nitric oxide synthase 
GABA   – gamma-aminobutyric acid 
GPCR   – G-protein-coupled receptor 
H1R   – histamine 1 receptor 
HDC   – histidine decarbocylase 
HPA   – hypothalamus – pituitary – adrenal axis 
HPT   – hypothalamus – pituitary – thyroid 
iNOS   – inducible nitric oxide synthase 
IR   – immunoreactive 
KO   – knock out 
MAP2   – microtubule-associated protein 2 
MC3R   – melanocortin 3 receptor 
MC4R   – melanocortin 4 receptor 
ME   – median eminence 
MR   – Mammillary recess 
DOI:10.15774/PPKE.ITK.2018.001
5 
 
mRNA  – messenger ribonucleic acid 
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I. Introduction 
The obesity epidemic is one of the major health problem of our days [1]. More than 60% of 
the population is overweight or obese in the USA and in Europe [2]. Obesity is not only 
esthetical problem, but it is also major risk factor of devastating diseases like type 2 diabetes, 
cardiovascular diseases, cancer etc… [1]. Despite the very high impact on population health 
and healthcare cost, efficient, non-invasive and side effect free treatment is currently not 
available against obesity. Large pharmaceutical companies try to develop efficient anti-obesity 
drugs based on the currently available drug targets without major breakthrough indicating the 
necessity of the discovery of novel anti-obesity drug targets. Therefore, better understanding 
of the regulatory mechanisms of energy homeostasis has critical importance in the fight 
against obesity. 
 Role of the hypothalamic arcuate nucleus (ARC) in the regulation of the energy I.1
homeostasis 
Information about the actual conditions of energy stores and about the consumed food is 
transmitted toward the central nervous system via peripheral nerves like the vagus nerve and 
the sensory fibers of sympathetic nerves and also by changes of the level of circulating 
hormones like leptin, ghrelin, cholecystokinin (CCK), peptide YY (PYY) and insulin [3]. This 
communication is critical for the maintenance of energy homeostasis [3]. Genetic alterations 
in these pathways cause obesity syndrome like in leptin or leptin receptor deficient animals or 
humans and in mice lacking insulin receptor in the brain [4-8]. 
A critical brain area that can sense these energy homeostasis related humoral signals is the 
ARC [3]. Ablation of the ARC by neonatal monosodium glutamate treatment induces obesity 
and leptin resistance [9]. 
At least two major energy homeostasis-related neuronal groups are located in the ARC [3]. 
There is a ventromedially located orexigenic neuronal population that expresses two potent 
orexigenic peptides, the neuropeptide Y (NPY) and the agouti-related protein (AGRP) [3]. 
These neurons also express the classical transmitter gamma-aminobutyric acid (GABA) [10] 
that has been also shown to stimulate food intake [11]. NPY is one of the most potent 
orexigenic signals [3]. Central administration of NPY causes marked increase of food intake, 
weight gain and increased adiposity [12]. The effect of NPY on the weight gain, however, 
cannot be exclusively accounted to its effect on the food intake. NPY also has potent 
inhibitory effect on the energy expenditure [13]. NPY elicits these effect via the G protein 
coupled postsynaptic Y1 and Y5 receptors [12]. 
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AGRP also increases the food intake and inhibits the energy expenditure [14]. The effect of 
AGRP on the energy homeostasis is mediated by two centrally expressed melanocortin 
receptors, the melanocortin 3 and 4 receptors (MC3R and MC4R). AGRP is the endogenous 
antagonist of these receptors [14]. Changes of energy availability regulate the expression of 
both peptides in the ARC neurons. While fasting stimulates the NPY and AGRP expression in 
these neurons, leptin administration inhibits the synthesis of the orexigenic peptides [3]. 
However, genetic ablation of NPY or AGRP has no major effect on the energy homeostasis; 
the critical importance of the orexigenic ARC neurons has been demonstrated by the life 
threatening anorexia of mice after ablation of the NPY/AGRP neurons [15, 16]. 
The proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript- 
(CART) synthesizing neurons located in the lateral part of the ARC has opposite effect on the 
regulation of energy homeostasis [3]. The POMC derived α-melanocyte-stimulating hormone 
(α-MSH) is well known about its potent anorexigenic effect [3]. Central administration of α-
MSH reduces food intake and simultaneously increases the energy expenditure [3]. The α-
MSH exerts its effect as the agonist of the MC3R and MC4R [17]. CART also inhibits food 
intake and can completely block the NPY induced feeding response [18]. Currently, little 
information is available about the effect of CART on the energy expenditure. The receptor(s) 
of CART has not been identified yet. 
The POMC/CART neurons are sensitive to the effects of peripheral energy homeostasis-
related hormones, like leptin and insulin [3], but these neurons are regulated differently than 
the NPY/AGRP neurons. Fasting inhibits the POMC and CART synthesis, while leptin 
administration stimulates the expression of these genes [3]. Despite the presence of leptin 
receptor in these cells, indirect effect of leptin that is mediated by GABAergic neurons is also 
critical in the regulation of the POMC/CART neurons [19]. 
The importance of the POMC/CART neurons in the regulation of energy homeostasis was also 
demonstrated by genetic studies. Genetic ablation of the POMC or MC4R genes results in 
morbid obesity in mice [20, 21]. Mutations of the melanocortin pathway also cause obesity in 
humans. Indeed, mutations of this pathway are the most frequent reason of the human 
monogenic obesity syndromes [22]. The absence of CART has less profound effect [23]. The 
CART knock out mice develop only late onset obesity [23]. In humans, a single nucleotide 
polymorphism (A1475G) of the CART gene is associated with human obesity syndrome [23]. 
The two feeding related neuronal populations of the ARC sense and integrate the energy 
homeostasis related signals and transmit it toward the so-called second order feeding related 
neuronal populations, including the hypothalamic paraventricular nucleus (PVN), the 
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hypothalamic dorsomedial nucleus (DMN) and the histaminergic neurons of the 
tuberomammillary nucleus (TMN).  
In addition to, the homeostatic regulation of the energy homeostasis, the feeding related 
neurons of the ARC are also involved in the regulation of food intake by adverse conditions 
like infection and stress [24, 25]. 
 Role of the PVN in the regulation of energy homeostasis I.2
The PVN is a triangular shaped nucleus that is located on the two sides of the upper part of the 
third ventricle. It consists of magnocellular and parvocellular parts [26]. The oxytocin- and 
vasopressin-synthesizing neurons of the magnocellular part are involved in the regulation of 
the posterior pituitary function [26].  
The parvocellular part can be further divided into five subdivisions: the anterior, 
periventricular, medial, ventral and lateral subdivisions and the dorsal cap [27]. The 
periventricular, and medial parvocellular subdivisions house both hypophysiotropic and non-
hypophysiotropic neurons, while the other parvocellular subdivisions house only non-
hypophysiotropic neurons. 
The hypophysiotropic neurons project to the external zone of the median eminence where they 
secrete their hypophysiotropic hormones into the extracellular space around the fenestrated 
capillaries [26]. These hormones reach the anterior pituitary via the hypophyseal portal 
circulation and regulate the hormone production of this endocrine gland. There are three types 
of hypophysiotropic neurons in the parvocellular part of the PVN: the somatostatin-, the 
corticotropin-releasing hormone- (CRH) and the thyrotropin-releasing hormone- (TRH) 
synthesizing neurons. The somatostatin neurons inhibit the growth hormone synthesis of the 
pituitary, while the hypophysiotropic CRH and TRH neurons are the central regulators of the 
hypothalamic-pituitary-adrenal (HPA) and thyroid (HPT) axes, respectively. All of these 
neuroendocrine axes have major impact on the regulation of the energy homeostasis. 
A large population of the non-hypophysiotropic neurons in the parvocellular part of the PVN 
regulates autonomic functions. These neurons project to the intermediolateral column of the 
spinal cord and to brainstem nuclei involved in the regulation of energy homeostasis like the 
nucleus tractus solitarii (NTS), the dorsal motor nucleus of vagus, the parabrachial nucleus 
and the catecholaminergic neurons of the ventral medulla [28]. Via these nuclei, the PVN 
multisynaptically linked to the pancreas, white and brown adipose tissue (BAT), liver and 
muscle [29-31]. Thus, these so-called preautonomic neurons of the PVN can regulate the 
energy homeostasis by controlling the lipid metabolism and storage, thermogenesis, 
gluconeogenesis and insulin synthesis [30].  
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However, the PVN receives energy homeostasis related inputs via multiple neuronal pathways 
and also via hormones, one of its most important energy homeostasis related input originates 
from the ARC [3]. Both the orexigenic and the anorexigenic neuronal groups densely 
innervate the neurons of the parvocellular part of the PVN [3]. In many instances, the same 
parvocellular neurons are innervated by both the orexigenic and anorexigenic ARC neurons 
[27].  
The PVN is a critical mediator of the effects of ARC neurons on the energy homeostasis [3]. 
Focal administration of NPY into the PVN markedly increases food intake [13], increases the 
carbohydrate utilization [32], decreases the energy expenditure and the uncoupling protein 1 
expression in the BAT [33, 34] and induces body weight gain [35]. 
Both postsynaptic NPY receptors, the Y1 and Y5, are expressed in the PVN [36], coupled to 
pertussis-toxin sensitive Gi/o proteins [37], and lead to the inhibition of cyclic adenosine 
monophosphate (cAMP) accumulation by inhibiting adenylate cyclase [38]. Some of the 
effects of NPY on energy expenditure are exerted through the regulation of TRH and CRH 
gene expression in the PVN via the modulation of the cAMP pathway [39-42]. NPY also has 
been shown to inhibit the GABAergic inputs of the parvocellular neurons of the PVN [43]. 
Similarly to NPY, intraPVN administration of AGRP also increases the food intake [44]. 
In contrast to the orexigenic peptides, α-MSH has potent anorexigenic effect when injected 
into the PVN [45]. Most of the effects of the α-MSH are mediated by the MC4R. The MC4R 
knockout (KO) mice are hyperphagic and have decreased energy expenditure [21]. Re-
expression of MC4R exclusively in the PVN rescues the hyperphagic phenotype of the MC4R 
KO mice, but has only little effect on the energy expenditure [46] substantiating the 
importance of the PVN in the mediation of the effect of melanocortins on the food intake. α-
MSH also regulates the HPA and HPT axes by stimulating the CRH and TRH gene expression 
in the PVN [47, 48]. 
 Retrograde transmitter systems in the parvocellular part of the PVN I.3
Using patch clamp electrophysiology, our laboratory showed that NPY inhibits both the 
GABAergic and the glutamatergic inputs of the parvocellular neurons [49]. These effects were 
completely prevented by the intracellular administration of the calcium chelator drug BAPTA1 
demonstrating that NPY inhibits the inputs of the parvocellular neurons by stimulating 
retrograde transmitter release of the target cells. [49]. The most widely utilized retrograde 
transmitter system in the brain is the endocannabinoid system [50]. In the central nervous 
system (CNS), the primary receptor of the endocannabinoid signaling system is the type 1 
                                                     
1 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
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cannabinoid receptor (CB1) [50]. The two most abundant endogenous ligands of this receptor 
are the 2-arachidonoylglycerol (2-AG) and the anandamide [50]. 2-AG is synthesized by 
postsynaptic neurons in the perisynaptic region and acts on the CB1 located in the perisynaptic 
region of the presynaptic terminals [50]. Activation of the CB1 inhibits the activity of the 
presynaptic terminals [50]. An important regulator of the endocannabinoid synthesis is the 
synaptic activity. The synthesizing enzyme of 2-AG, the diacylglycerol lipase α (DAGLα), is 
activated in response to increased synaptic activity which effect is mediated by metabotropic 
receptors coupled to phospholipase C beta (PLCβ) like metabotropic glutamate receptor 1 and 
5, muscarinic acetylcholine (mACh) receptor M1 and M3 [51]. 
Our laboratory has shown that CB1 is present in both the inhibitory and excitatory terminals 
innervating the parvocellular neurons in the PVN [52] and the endocannabinoid system has 
been shown to mediate the effects of ghrelin and the glucocorticoids on the parvocellular 
neurons of the PVN [53, 54].  
We have found that inhibition of CB1 by AM2512 prevents the effect of NPY on the 
GABAergic input of parvocellular neurons [49]. However, the dose of AM251 that were 
sufficient to prevent the effect of ghrelin on the glutamatergic inputs of the parvocellular 
neurons [53], did not prevent the effects of NPY on the glutamatergic inputs [49] suggesting 
that other retrograde signaling system(s) is also involved in the mediation of the NPY induced 
effects (Fig. 1).  
Nitric oxide (NO) is a gaseous transmitter [55]. NO is synthesized by a family of the NO 
synthesizing (NOS) enzymes: the neuronal NOS (nNOS), the inducible NOS (iNOS) and the 
endothelial NOS (eNOS) [55]. Among these enzymes, the nNOS is present in neurons [55]. 
The most sensitive receptor of NO is the soluble guanylate cyclase (sGC) [55]. In the 
hippocampus, both the nNOS and the sGC can be observed in both pre- and postsynaptic 
localization [56] suggesting that NO can serve as both anterograde and retrograde transmitter. 
Electrophysiological experiments also provided evidence supporting the retrograde transmitter 
role of NO and the interaction of the endocannabinoid and NO signaling in the presynaptic 
plasticity in the hippocampal formation [57]. 
However, nNOS is also present in the PVN, little is known about the localization of the 
elements of NO signaling in this nucleus and it is also unknown whether NO is utilized as a 
retrograde transmitter in this nucleus [58]. 
 
                                                     
2
 biarylpyrazole cannabinoid receptor antagonist 
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Figure 1 Schematic illustration of the effect of NPY on the parvocellular neurons in the 
hypothalamic PVN.  
NPY acts via the Y1 and Y5 receptors in the parvocellular part of the hypothalamic PVN. The 
receptor activation inhibits gene transcription y decreasing the cAMP level, but at the same 
time, it can activate retrograde messengers systems via modulation of the intracellular Ca2+ 
levels. Thus, NPY can inhibit the synaptic inputs of the parvocellular neurons via retrograde 
messengers. Nu –nucleus, Glut – glutamatergic terminals, GABA – GABAergic terminals, 
NPY-neuropeptide Y, Y1R-NPY receptor type 1, Y5R- NPY receptor type 5 
 Feedback regulation of the hypophysiotropic TRH neurons I.4
One of the neuronal groups of the PVN that play critical role in the regulation of the energy 
homeostasis is the group of the hypophysiotropic TRH neurons [27]. These neurons control 
the hormone production of the thyroid gland through the regulation of the TSH secretion of 
Retrograde tranmitters 
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the thyrotroph cells in the anterior pituitary [27]. The thyroid hormones are important 
regulators of the energy homeostasis [27]. In the absence of thyroid hormones, the basal 
metabolic rate is decreased by 30% and the cold induced thermogenesis is also absent in 
hypothyroid animals [27].  
The main regulator of the HPT axis is the negative feedback effect of thyroid hormones that 
ensure the relatively stable circulating thyroid hormone levels [27]. Thus, when the peripheral 
levels of thyroid hormones are increased, the TRH synthesis is inhibited by thyroid hormones 
[27]. The hypophysiotropic TRH neurons contain the thyroid hormone β2 receptor (TRß2) that 
is essential for the feedback regulation of these cells [27]. In addition, implantation of T33 
adjacent to the PVN inhibits the TRH expression on the side of the implantation [27]. 
However, restoration of the circulating T3 levels in hypothyroid animals without 
administration of the prohormone T44 is not sufficient to normalize the TRH expression in the 
PVN [27]. These data demonstrate that hypothalamic conversion of the prohormone T4 to its 
active form, T3, is necessary for the feedback regulation of the TRH neurons. In the 
hypothalamus, T4-T3 conversion is catalyzed by the type 2 deiodinase enzyme (D2) [59]. D2 
activity or mRNA, however, is not present in the PVN where the hypophysiotropic TRH 
neurons reside [60]. D2 is synthesized in the hypothalamus by a special glial cell types, the 
tanycytes [60]. Tanycytes line the lateral wall and the floor of the third ventricle behind the 
optic chiasm. The long basal process of these cells projects to the hypothalamic dorsomedial 
and ventromedial nuclei, into the ARC and into the external zone of the median eminence 
(ME) [27]. Thus, the cell bodies of the TRH neurons are located relatively far from the thyroid 
hormone activating cells of the hypothalamus. In the external zone of the ME, however, end 
feet processes of the tanycytes and the axon terminals of the hypophysiotropic TRH neurons 
are closely associated raising the possibility that T3 released from the tanycytes may be taken 
up by the hypophysiotropic terminals and transported to the cell bodies of TRH neurons where 
T3 could bind to the nuclear TRβ2 [27]. The thyroid hormone transport is mediated by thyroid 
hormone transporters [27]. The main thyroid hormone transporters are the monocarboxylate 
transporter 8 (MCT8), organic anion-transporting polypeptide 1c1 (OATP1C1), Lat1 and 
Lat25[61]. The main thyroid hormone transporter of neurons is MCT8. The absence of MCT8 
causes serious neurological symptom in humans and upregulation of the HPT axis in both 
humans and mice [62, 63] suggesting that MCT8 is involved in the feedback regulation of the 
HPT axis. However, the presence of MCT8 was demonstrated in tanycytes [64], data were not 
available about the presence of this transporter in hypophysiotropic axons. The presence of 
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MCT8 in the axon terminals of the hypophysiotropic TRH neurons would suggest that the 
axon terminals of the hypophysiotropic TRH axons are able to take up T3 in the ME. The 
importance of this question is underlined by the different kinetics of the T4 and T3 transport 
through the blood brain barrier (BBB). T3 can far more efficiently pass through the BBB than 
T4 [27]. This is however not the case in the external zone of the ME which brain region is 
located outside of the BBB. Thus, the site of thyroid hormone uptake determines whether the 
hypophysiotropic TRH neurons can only sense the T3 that is activated within the BBB or 
these cells can sense a mixture of the T3 originating from the circulation and released by the 
tanycytes in the ME (Fig. 2). 
 
                         
 
Figure 2 Schematic illustration of thyroid hormone negative feedback mechanism 
Thyroid hormones exert negative feedback effect on the hypophysiotropic TRH neurons. This 
feedback mechanism requires central thyroid hormone activation. This T4 to T3 conversion is 
catalyzed by the type 2 deiodinase (D2) that is expressed by the tanycytes lining the wall of the 
third ventricle. It was not clear, how T3 released from tanycytes can reach the 
hypophysiotropic TRH neurons in the PVN. T3 may diffuse through the neuropil. An 
alternative hypothesis is that the axons of TRH neurons may take up the T3 in the external 
zone of the median eminence where the axons of hypophysiotropic TRH neurons and the 
endfeet processes of tanyctes are closely associated D2- type 2 deiodinase enzyme, ME – 
Hypophyis 
T4 Pc 
III ventricle PVN 
Tc Tc Tc 
Thyroid gland 
 
TRH 
TRH 
TSH 
T4 T4 T4 
D2 D2 D2 
T3, T4 
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median eminence, PVN – paraventricular nucleus, TRH – thyrotropin-releasing-hormone, 
MCT8 – monocarboxylate transporter 8, T3 – triiodothyronine, T4 – thyroxine, TSH – 
thyroid-stimulating hormone, Pc – portal capillary 
 
 Role of TRH neurons in the regulation of food intake I.5
It was demonstrated decades ago that central administration of TRH decreases food intake and 
the time spent with feeding [65]. TRH can inhibit even the vigorous feeding when food is 
reintroduced after a period of fasting [65]. Despite the very robust anorexigenic effect of TRH, 
very little information is available which TRH cell population and where exerts this effect.  
In addition to the very well-known hypophysiotropic TRH neurons in the medial and 
periventricular parvocellular subdivisions of the PVN, there are many non-hypophysiotropic 
TRH synthesizing neuronal groups in the brain including the TRH neurons in the anterior and 
lateral parvocellular parts and dorsal cap of the PVN and TRH neurons in the DMN, lateral 
hypothalamus, perifornical region, bed nucleus of stria terminalis (BNST) [66].  
Our laboratory has shown [67] that a seemingly continuous population of TRH neurons in the 
perifornical region and BNST area expresses a second anorexigenic peptide, the urocortin 3 
(UCN3) and demonstrated that these neurons project to the lateral part of the ARC. The 
presence of two anorexigenic peptides in the same neurons and the projection of these cells to 
the lateral part of the ARC where the anorexigenic POMC neurons are located raised the 
possibility that the TRH/UCN3 neurons of the perifornical area/BNST region could be 
involved in the regulation of food intake. 
Another cell population that may be involved in the mediation of the anorexigenic effects of 
TRH is the histaminergic neurons of the TMN in the posterior hypothalamus. Similarly to 
TRH, central administration of histamine reduces food intake in a number of experimental 
models [68-70]. Furthermore, the absence of the histamine-synthesizing enzyme, the histidine 
decarboxylase (HDC), results in late onset obesity and hyperphagia [71] demonstrating the 
anorexigenic role of histamine.  
Central administration of TRH not only decreases food intake in a dose-dependent manner, but 
also increases the concentration of histamine and t-methylhistamine (a major metabolite of 
neuronal histamine) in the TMN [72] suggesting that the histaminergic neurons may be 
involved in the mediation of TRH induced anorexia. This hypothesis is further supported by 
the data that the anorexic effects of TRH could be attenuated by pretreatment with the 
irreversible HDC inhibitor, α-fluoro-methyl histidine [72] and that TRH can excite the 
histaminergic neurons [73]. Based on these important functional data, we hypothesized that 
the identification of the sources of the TRH-containing inputs of the histaminergic neurons can 
be used to identify anorexigenic TRH cell populations. However, it was unknown, whether 
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TRH neurons innervate the histaminergic neurons and whether TRH neurons innervate the 
histaminergic neurons in all five subnuclei of the TMN or the communication of these two 
systems is localized to only certain TMN subnuclei. Therefore, the detailed description of the 
relationship of the TRH axons and the histaminergic neurons was necessary to provide 
anatomical data for later track tracing studies. 
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II. Specific aims 
To better understand the hypothalamic network regulating energy homeostasis we: 
 
1. Elucidated the ultrastructural localization of the elements of the NO transmitter system in 
the PVN. 
2. Studied whether the NO and the endocannabinoid systems are associated to the same 
synapses of the parvocellular neurons of the PVN. 
3. Examined the role of the endocannabinoid and the NO systems of the PVN in the mediation 
of the NPY induced regulation of energy homeostasis  
4. Determined the presence of MCT8 thyroid hormone transmitter in the axon terminals of the 
hypophysiotropic TRH neurons. 
5. Examined the role of TRH/UCN3 neurons of the perifornical area/BNST region in the 
regulation of the feeding related neuronal groups of the hypothalamic arcuate nucleus. 
6. Studied the TRH-containing innervation of the histaminergic neurons in TMN. 
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III. Materials and methods 
 Animals III.1
The experiments were carried on adult, male Wistar rats (Charles Rivers, Wilmington, MA), 
CD1 mice (Charles Rivers, Wilmington, MA) and MCT8 KO [74] mice housed under 
standard environmental conditions (light between 06:00 and 18:00 h, temperature 22±1 °C, rat 
chow and water ad libitum). The used animals are listed in the description of each experiment. 
All experimental protocols were reviewed and approved by the Animal Welfare Committee at 
the Institute of Experimental Medicine of the Hungarian Academy of Sciences. 
 Colchicine treatment III.2
As peptides are rapidly transported into axons, immunocytochemistry can detect the axons of 
peptide producing neurons, but can only visualize the perikarya of only a small proportion of 
these cells. The visualization of peptide synthesizing perikarya can be facilitated by the central 
administration of the microtubules association inhibitor colchicine, which treatment prevents 
the axonal transport [75]. Therefore, colchicine-treatment of rats was performed in studies 
IV.3 and IV.4. Rats anaesthetized with a mixture of ketamine and xylazine (ketamine 50 
mg/kg, xylazine 10 mg/kg body weight, ip.) were injected intracerebroventricularly with 100 
µg colchicine in 5 µl 0.9% saline under stereotaxic control to facilitate the visualization of 
peptides in perikarya in the ARC and TMN. Twenty hours later, the animals were 
anaesthetized and perfused with fixative. 
 Fixation of animals for immunocytochemistry at light and electron III.3
microscopic levels 
Under general anaesthesia (ketamine 50 mg/kg, xylazine 10 mg/kg body weight, ip.), the 
animals were perfused transcardially by 10 ml phosphate buffer saline (PBS) pH 7.5 followed 
by fixative solution. The different fixatives used in the studies are summarized in Table 1. For 
light microscopic studies, we used 4% PFA (pH 7.4) to perfuse the animals. This fixative is 
appropriate for light microscopic studies, and compatible for most antibodies, but it does not 
provide sufficient tissue preservation for ultrastructural studies. Three of the used antibodies, 
the sheep and mouse anti-TRH sera and the sheep anti-histamine serum require acrolein-
containing fixative that is appropriate for both light- and electron microscopic studies. The 
rabbit anti-nNOS and the rabbit anti-sGCα sera were not compatible with strong fixatives like 
acrolein and glutaraldehyde that are routinely used for ultrastructural studies. Therefore, 
double pH fixatives were used for ultrastructural studies with these antibodies. First the 
animals were perfused with 4% PFA in sodium-acetate buffer pH 6.0, followed by 4% PFA in 
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borate buffer pH 8.5. This combination provides good ultrastructure and was compatible with 
these two antisera. After perfusion, the brains were rapidly removed and stored in 4% 
paraformaldehyde (PFA) in 0.1M phosphate buffer (PB), pH 7.4 for 2 h for light microscopy 
or 24 h for electron microscopy. The different antibodies used in the studies are summarized in 
Table 2-4. 
 
Table 1 Summary of the fixation methods and the number of used animals 
Experiments Fixative solution 
Used amount 
of the 
fixative 
solution 
Number of 
used 
animals 
IV.1.1- 2. Ultrastructural localization of 
nNOS, sGCα1 and CB1 
10 ml of 4% PFA in 
Na-acetate buffer, pH 
6.0, followed by 50 ml 
of 4% PFA in Borax 
buffer, pH 8.5 
50 ml/mouse 4 
IV.1.3. Double-, triple- and quadruple-
labeling light microscopic 
immunocytochemistry using MAP2, 
VGLUT1, VGLUT2, VIAAT, CB1 and 
DAGLα antibodies 
4% PFA in 0.1 M PB, 
pH 7.4 
50 ml/mouse 3 
IV. 2. 1. Light microscopic detection of 
MCT8 
4% PFA in 0.1 M PB, 
pH 7.4 
50 ml/mouse 
or 150 ml/rat 
3 
3 
IV.2.2. Ultrastructural detection of MCT8 
2% PFA + 4% acrolein 
in 0.1 M PB, pH 7.4 
150 ml/rat 3 
IV.3. Double- and triple-labeling light- and 
double-labeling electron microscopic 
examination of the TRH and UCN3-IR 
innervation of the α-MSH-IR neurons 
3% PFA + 1 % 
acrolein in 0.1 M PB, 
pH 7.4 
150 ml/rat 3 
IV.4. Double-labeling light- and electron 
microscopic examination of the TRH-IR 
innervation of the histaminergic neurons 
2% PFA + 4% acrolein 
in 0.1 M PB, pH 7.4 
150 ml/rat 3 
 
 Tissue preparation for light microscopic immunohistochemistry III.4
The brains were cryoprotected in 30% sucrose in PBS at 4 °C overnight, then frozen in 
powdered dry ice. Serial, 25 μm thick coronal sections were cut on a freezing microtome 
DOI:10.15774/PPKE.ITK.2018.001
24 
 
(Leica, Wetzlar, Germany), collected in cryoprotectant solution (30% ethylene glycol; 25% 
glycerol; 0.05 M phosphate buffer (PB) and stored at −20 °C until use. The free aldehyde 
groups in acrolein fixed tissues can bind antibodies, therefore these aldehyde groups can cause 
high background signal [76]. To prevent this effect, acrolein fixed tissues were treated with 
1% sodium borohydride in distilled water (DW) for 30 min. All tissues were treated with 0.5% 
Triton X-100/0.5% H2O2 in PBS for 15 min to increase antibody penetration and reduce 
endogenous peroxidase activity. To limit the nonspecific antibody binding, the sections were 
treated with 2% normal horse serum (NHS) in PBS for 20 min.  
 
Table 2 Summary of the primary and secondary antibodies used in light microscopic studies 
Study 
number 
Used primary antibodies and sources Dilution Secondary antibody 
IV.2. 
rabbit anti-MCT8 (kind gift from Dr. TJ 
Visser Rotterdam, The Netherlands) 
1:5000 –
10000 
biotinylated donkey anti-rabbit IgG, 
1:500; Jackson ImmunoResearch 
IV.4. 
sheep anti-TRH (#08W2) [67, 77] 1:50000 
biotinylated donkey anti-sheep IgG, 
1:500; Jackson ImmunoResearch 
sheep anti-histamine [78] 1:1000 
biotinylated donkey anti-sheep IgG, 
1:500; Jackson ImmunoResearch 
 
 Tissue preparation for ultrastructural studies  III.5
After the perfusion with fixative, the brains were rapidly removed and postfixed in 4% PFA in 
0.1M PB, pH 7.4 and overnight at 4°C. Serial, 25-50 μm thick, coronal sections were cut on a 
Leica VT 1000S vibratome (Leica Microsystems, Wetzlar, Germany) and collected in PBS. 
Those sections which were fixed with acrolein containing fixative were treated with 1% 
sodium borohydride in 0.1 M PB, pH 7.4, for 30 min. All sections were treated by 0.5% H2O2 
in PBS for 15 min. The sections were cryoprotected in 15% sucrose in PBS for 15 min at room 
temperature (RT) and in 30% sucrose in PBS overnight at 4 °C. The sections were placed in a 
tinfoil dish or an Eppendorf tube and quickly frozen over liquid nitrogen, then thawed at RT. 
This cycle was repeated three times to improve antibody penetration into the tissue. To reduce 
the nonspecific antibody binding, the sections were treated with 2% NHS in PBS for 20 min. 
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Table 3 Summary of the primary and secondary antibodies used in fluorescence microscopic 
studies 
Study 
number 
Used primary antibodies and sources Dilution Secondary antibody 
IV. 1.2. 
rabbit anti-CB1 serum (Abcam, 
Cambridge UK) [79] 
1 µg/ml 
Alexa 488-conjugated donkey anti-rabbit 
IgG, 1:200; Life Technologies 
rabbit anti- DAGLα serum (Abcam, 
Cambridge UK) [80] 
1 µg/ml 
Alexa 647-conjugated donkey anti-rabbit 
IgG, 1:200; Life Technologies 
mouse anti-MAP2 antibody (Millipore) 1 µg/ml 
Alexa 405-conjugated donkey anti-mouse 
IgG, 1:200; Life Technologies 
guinea pig anti-nNOS serum (Abcam, 
Cambridge UK) [81] 
1 µg/ml 
Alexa 555-conjugated donkey anti-guinea 
pig IgG, 1:200; Life Technologies 
goat anti-VGLUT1 serum (Abcam, 
Cambridge UK) [82] 
1 µg/ml 
Alexa 555-conjugated donkey anti-goat IgG, 
1:200; Life Technologies 
goat anti-VGLUT2 serum (Abcam, 
Cambridge UK) [82] 
1 µg/ml 
Alexa 555-conjugated donkey anti-goat IgG, 
1:200; Life Technologies 
goat anti-VIAAT serum (Abcam, 
Cambridge UK) [82] 
1 µg/ml 
Alexa 555-conjugated donkey anti-goat IgG, 
1:200; Life Technologies 
IV.2. 
rabbit anti-MCT8 serum kind (gift from 
Dr. TJ Visser Rotterdam, The 
Netherlands) 
1:1000 
Alexa 555-conjugated donkey anti-goat IgG, 
1:500; Life Technologies 
sheep anti-TRH serum #08W2 [67] 1:1500 
Fluorescein DTAF-conjugated donkey anti -
sheep IgG, 1:50;Jackson ImmunoResearch 
IV.3 
rabbit anti-UCN3 serum (kind gift from 
Dr. WW.Vale La Jolla, CA) [67] 
1:60000 
biotinylated donkey anti-rabbit IgG, at 
1:500; Jackson ImmunoResearch 
Fluorescein DTAF-conjugated Streptavidin 
1:300; Jackson ImmunoResearch 
mouse anti-TRH serum [83, 84] 1:4000 
Alexa 555-conjugated donkey anti-mouse 
IgG, 1:500; Jackson ImmunoResearch 
sheep anti-α-MSH serum 1:20000 Cy5-conjugated donkey anti-sheep IgG, 
1:100; Jackson ImmunoResearch 
sheep anti-NPY serum (kind gift from I. 
Merchenthaler, Baltimore MD) 
1:8000 
Cy5-conjugated donkey anti-sheep IgG, 
1:100; Jackson ImmunoResearch 
IV.4. 
mouse anti-TRH serum 1:4000 
Alexa 555-conjugated donkey anti-mouse 
IgG, 1:500; Jackson ImmunoResearch 
sheep anti-histamine serum 1:20000 
donkey biotinylated anti-sheep IgG, 1:500 
fluorescein-conjugated streptavidin, 1:250; 
Vector Laboratories 
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Table 4 Summary of the primary and secondary antibodies used in electron microscopic 
studies 
Studies 
number 
Used primary antibody and sources Dilution Secondary antibody 
IV.1.1. 
rabbit anti-nNOS serum (Zymed 
Laboratories, Waltham, MA) 
1:200 
donkey anti-rabbit IgG-conjugated  with 0.8 nm 
colloidal gold, 1:100; Electron Microscopy 
Sciences 
IV.1.1. 
rabbit anti-sGCα1 serum (Sigma 
Aldrich St. Louis, MA) 
1:4000 
biotinylated donkey anti-rabbit IgG, 1:500; 
Jackson Immunoresearch 
IV.1.3. 
rabbit anti-nNOS serum (Zymed 
Laboratories, Waltham, MA) 
1:200 
donkey anti-rabbit IgG-conjugated with 0.8 nm 
colloidal gold, 1:100; Electron Microscopy 
Sciences 
sheep anti-CB1 serum (kind gift from 
Dr. Watanabe, Sapporo, Japan) 
1:800 
biotinylated donkey anti-sheep IgG, 1:500; 
Jackson ImmunoResearch 
IV.2. 
rabbit anti-MCT8 serum (kind gift 
from Dr. TJ Visser, Rotterdam, The 
Netherlands) 
1:20000 
biotinylated donkey anti-rabbit IgG, 1:500; 
Jackson ImmunoResearch 
IV.3. 
sheep anti-α-MSH serum (kind gift 
from Dr. JB Tatro, Boston, MA) 
1:1000 
donkey anti-sheep IgG-conjugated  with 0.8 nm 
colloidal gold, 1:100; Electron Microscopy 
Sciences 
rabbit anti-UCN3 serum (kind gift 
from Dr. WW. Vale, La Jolla, CA) 
1:1000 
biotinylated donkey anti-rabbit IgG, 1:500; 
Jackson ImmunoResearch 
IV.4. 
mouse anti-TRH serum 1:10000 
biotinylated donkey anti-mouse IgG, 1:500; 
Jackson ImmunoResearch 
sheep anti- histamine serum 1:2000 
donkey anti-sheep IgG-conjugated  with 0.8 nm 
colloidal gold, 1:100; Electron Microscopy 
Sciences 
 Immunocytochemistry for ultrastructural localization of nNOS III.6
Sections pretreated as described in III.5 were incubated in rabbit anti-nNOS serum (1:200, 
Zymed Laboratories, Waltham, MA) for 4 days at 4 °C. After rinsing in PBS and in 0.1% cold 
water fish gelatin (Aurion, Wageningen, Netherlands) /1% bovine serum albumin (BSA) in 
PBS, the sections were incubated in donkey anti-rabbit IgG-conjugated with 0.8 nm colloidal 
gold (Electron Microscopy Sciences, Fort Washington, PA) diluted at 1:100 in PBS containing 
0.1% cold water fish gelatin and 1% BSA for 1 h. After washing, the sections were fixed in 
1.25% glutaraldehyde (Electron Microscopy Sciences, Fort Washington, PA) in 0.1M PB for 
10 min. The gold particles were silver intensified with the Aurion R-Gent SE-LM Kit (Aurion, 
Wageningen, The Netherlands) after rinsing in 0.2M sodium citrate, pH 7.5. 
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 Immunocytochemistry for ultrastructural localization of sGCα1 III.7
Sections pretreated as described in III.5 were placed in rabbit anti-sGCα1 serum (1:4000, 
Sigma Aldrich, St. Louis, MO ) diluted in serum diluent for 4 days at 4 °C. After rinsing in 
PBS, the sections were incubated in biotinylated donkey anti-rabbit IgG diluted at 1:500 
(Jackson Immunoresearch Lab, West Grove, PA) in serum diluent. After rinsing in PBS, and 
treated with avidin-biotin-complex (ABC elite; 1:1000 dilution; Vector laboratories, 
Burlingame, CA), the sGCα1-immunoreactivity was detected with NiDAB developer (0.05% 
DAB, 0.15% nickel-ammonium-sulfate and 0.005% H2O2 in 0.05M Tris buffer pH 7.6). The 
immunoreaction product was silver-intensified by using Gallyas method [85].  
 Double-labeling immunocytochemistry for ultrastructural examination of the III.8
distribution of nNOS and CB1 
Sections pretreated as described in III.5 were placed in a mixture of rabbit anti-nNOS serum 
(1:200) and sheep anti-CB1 serum (1:800, kind gift from Dr. Watanabe, Sapporo, Japan) for 4 
days at 4°C. After rinsing in PBS and 0.1% cold water fish gelatin/1% BSA in PBS, they were 
incubated in a cocktail of donkey anti-rabbit IgG-conjugated with 0.8 nm colloidal gold 
(1:100) diluted at 1:100 and biotinylated donkey anti-sheep IgG (Jackson Immunoresearch 
Lab, West Grove, PA) diluted at 1:500 in PBS containing 0.1% cold water fish gelatin and 1% 
BSA. After washing, the sections were fixed in 1.25% glutaraldehyde in 0.1M PB for 10 min. 
The gold particles were silver intensified with the Aurion R-Gent SE-LM Kit after rinsing in 
0.2M sodium citrate, pH 7.5, followed by treatment in ABC (1:1000). The CB1-
immunoreactivity was detected with NiDAB developer. 
 Quadruple-labeling immunofluorescence of the elements of the endocannabinoid III.9
and NO signaling systems and markers of glutamatergic and GABAergic neurons in the 
PVN 
Sections pretreated as described in III.4 were incubated in the mixture of primary antibodies 
overnight (1 µg/ml), and then in a mixture of fluorochrome-conjugated species-specific 
secondary antibodies for 2 h at (1:200; Life Technologies; Carlsbad, CA). The following 
primary antibodies were used: rabbit anti-CB1 (Abcam, Cambridge, UK) [79], rabbit anti-
DAGLα (Abcam, Cambridge, UK) [80], mouse anti-MAP2 antibody (Millipore, Billerica, 
MA), guinea pig anti-nNOS (Abcam, Cambridge, UK) [81], goat anti-VGLUT1 (Abcam, 
Cambridge, UK) [82], goat anti-VGLUT2 (Abcam, Cambridge, UK) [82] and goat anti-
VIAAT (Abcam, Cambridge, UK) [82] antibodies. PBS containing 0.1% Tween20 was used 
as dilution and as washing buffer.  
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 Light microscopic detection of MCT8 III.10
Sections pretreated as described in III.4 containing the ME, were incubated in rabbit anti-
MCT8 serum (rat and WT and MCT8 KO mouse tissues; 1:5000–10000; kind gift of Dr. TJ 
Visser Rotterdam, The Netherlands) for 2 days at 4°C. The sections were then incubated in 
biotinylated donkey anti-rabbit IgG (1:500) for 2 hours, followed by incubation in ABC 
(1:1000) for 1 hour. The peroxidase signal was visualized with a NiDAB developer. The 
resulted reaction product was silver-gold-intensified using the Gallyas method [86].  
 Ultrastructural detection of MCT8-immunoreactivity in the rat ME III.11
To study the cellular and subcellular distribution of MCT8 in the rat ME, sections pretreated 
as described in III.5 were incubated in the primary antibody (anti-MCT8 antiserum; 1:20000) 
for 36–48 h at 4°C, followed by biotinylated donkey anti-rabbit IgG (1:500) for 2 h and ABC 
(1:1000) for 1.5 h. The immunoreactive (IR) sites were visualized with NiDAB developer. 
Finally the immunoreaction product was silver-gold intensified [86]. 
 Double labeling immunofluorescence for MCT8 and TRH III.12
Sections pretreated as described in III.4 incubated in rabbit anti-MCT8 serum (1:1000, 48 h), 
and detected with Alexa 555-conjugated anti-rabbit IgG (1:500, 2 h, Thermo Fisher Scientific, 
Waltham, MA). Then, the sections were immersed in sheep anti-TRH serum (#08W2, 1:1500) 
followed by Fluorescein DTAF-conjugated donkey anti sheep IgG (1:50, 2h, Jackson 
ImmunoResearch, West Grove, PA).  
 Triple-labeling immunofluorescence for TRH, UCN3 and α-MSH or NPY III.13
One-in-four series of sections from each brain pretreated as described in III.4 were incubated 
in rabbit anti-UCN3 serum (kind gift from Dr. WW Vale, La Jolla, CA) at 1:60000 dilution, 
preabsorbed with 75 µg/ml rat CRF (corticotropin-releasing factor) (Bachem, Bubendorf, 
Switzerland), mouse anti-TRH serum [84] at 1:4000 and either sheep anti-α-MSH serum (kind 
gift from Dr. JB Tatro, Boston, MA) [78] at 1:20000 or sheep anti-NPY serum (kind gift from 
Dr. I. Merchenthaler, Baltimore MD) at 1:8000 for 2 days at 4oC. Then, sections were treated 
with biotinylated donkey anti-rabbit IgG (1:500) for 2 h, followed by the ABC (1:1000) for 2 
h. After washes in PBS, sections were subjected to biotinylated tyramide signal amplification 
using the tyramide signal amplification (TSA) kit according to the manufacturer’s instructions 
(Life technologies, Carlsbad, CA). After further washes, the sections were incubated in a 
mixture of Fluorescein DTAF-conjugated Streptavidin (1:300, Jackson ImmunoResearch, 
West Grove, PA), Alexa 555-conjugated donkey anti-mouse IgG (1:500, Jackson 
DOI:10.15774/PPKE.ITK.2018.001
29 
 
ImmunoResearch, West Grove, PA) and Cy5-conjugated donkey anti-sheep IgG (1:100, 
Jackson ImmunoResearch, West Grove, PA) for 2 h.  
 Double-labeling immunocytochemistry for ultrastructural examination of the III.14
UCN3-IR innervation of the α-MSH neurons in the ARC 
Sections pretreated as described in III.5 were placed in a mixture of sheep anti-α-MSH serum 
(1:1000) and rabbit anti-UCN3 serum (1:1000) preabsorbed with 75 µg/ml rat CRF for 4 days 
at 4 °C. After rinsing in PBS and in 0.1% cold water fish gelatin/1% BSA in PBS, the sections 
were incubated in donkey anti-sheep IgG-conjugated  with 0.8 nm colloidal gold (Electron 
Microscopy Sciences, Fort Washington, PA) diluted at 1:100 and biotinylated donkey anti-
rabbit IgG diluted at 1:500 in PBS containing 0.1% cold water fish gelatin and 1% BSA. After 
washing, the sections were fixed in 1.25% glutaraldehyde in 0.1M PB for 10 min at RT. After 
further rinsing in PBS, the sections were washed in Aurion ECS buffer (1:10, Aurion, 
Wageningen, The Netherlands) diluted in DW. The gold particles were silver intensified with 
the Aurion R-Gent SE-LM Kit after rinsing in 0.2M sodium citrate, pH 7.5. After treatment in 
ABC (1:1000), the UCN3-immunoreactivity was detected with NiDAB developer. 
 Double labeling immunocytochemistry for TRH and histamine in the TMN  III.15
Coronal sections through the posterior hypothalamus were pretreated as described above in 
III.4 and then were incubated in sheep TRH antiserum [67, 83] at 1:50000 dilution in PBS 
containing 2% NHS and 0.2% sodium azide for 2 days at 4 °C. After rinses in PBS, the 
sections were incubated in biotinylated donkey anti-sheep IgG for 2 h (1:500; Jackson 
ImmunoResearch, West Grove, PA) followed by treatment in ABC (1:1000) in 0.05M Tris 
buffer for 1 h at RT. The immunoreaction was developed with NiDAB developer. The 
chromogen was then further intensified by a silver intensification technique to yield a black 
precipitate [87] After visualization of TRH, the sections were incubated in sheep antiserum to 
histamine [78] at 1:1000 dilution in antiserum diluent for 2 days at 4 °C, followed by 
treatment in biotinylated donkey anti-sheep IgG (1:500) and in ABC (1:1000). The 
immunolabeling was visualized by DAB developer (0.025% DAB/0.0036% H2O2 in 0.05M 
Tris buffer pH 7.6) to yield a brown reaction product. Using the silver intensified NiDAB and 
DAB fluorochromes sequentially, two antibodies raised the same species can be used for 
innervation studies without cross-reaction [78, 88] because the use of low pH gold chloride 
solution during the silver intensification procedure elutes the antigens from the sections [89] 
and the black silver precipitate completely fills the profiles and thereby obscures any potential, 
brown, DAB precipitate. Thus, the TRH-IR fibers were labeled by black, silver-intensified Ni-
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DAB, and the histamine-IR neurons were labeled with brown DAB, which chromogens could 
be easily distinguished in the same section.  
 Double-labeling immunofluorescence for TRH and histamine in the TMN III.16
To facilitate the quantification of the TRH-IR innervation of the histaminergic neurons, 
confocal microscopic analyses of double-labeled immunofluorescent sections was performed. 
Pretreated sections, as described in III.4, containing the TMN were incubated in a mixture of 
mouse anti-TRH serum [90] at 1:4000 dilution and sheep anti-histamine serum (1:20000) for 2 
days at 4 °C. After washing in PBS, the sections were immersed in a mixture of Alexa 555-
conjugated donkey anti-mouse IgG (1:500, Jackson ImmunoResearch, West Grove, PA) and 
biotinylated donkey anti-sheep IgG (1:500) for 2 h at room temperature. This was followed by 
treatment in ABC (1:1000) diluted in 0.05M Tris buffer for 1 h at room temperature. The 
sections were then rinsed in PBS and the immunoreaction product was amplified by TSA kit 
according to the manufacturer’s instructions. After further rinses, the sections were incubated 
in Fluorescein DTAF-conjugated Streptavidin (1:250) for 1 h.  
 Double-labeling immunocytochemistry for ultrastructural examination of the III.17
TRH-IR innervation of the histamine-IR neurons in the TMN 
Sections pretreated as described in III.5 were incubated in mouse anti-TRH serum (1:10000) 
for 4 days at 4 °C, followed by biotinylated donkey anti-mouse IgG (1:500) for 20 h at 4 °C 
and ABC (1:1000) for 1 h at RT. Immunoreactivity was detected with DAB developer. The 
sections were then placed into sheep anti-histamine serum (1:250) for 2 days at 4 °C and after 
rinsing in PBS and in 0.1% cold water fish gelatin/1% BSA in PBS, the sections were 
incubated in donkey anti-sheep IgG-conjugated with 0.8 nm colloidal gold diluted at 1:100 in 
PBS containing 0.1% cold water fish gelatin and 1% BSA. The sections were washed in the 
same diluent and PBS, followed by a 10 min treatment in 1.25% glutaraldehyde in PBS. After 
rinsing in Aurion ECS buffer (1:10), the gold particles were silver intensified with the R-Gent 
SE-LM kit [91].  
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Table 5 Summary of the antibodies 
Used primary antibody Source Reference 
goat anti-VGLUT1 serum Abcam, Cambdridge, UK [82] 
goat anti-VGLUT2 serum Abcam, Cambdridge, UK [82] 
goat anti-VIAAT serum Life technologies, Waltham, MA [82] 
guinea pig anti-nNOS serum Thermo Fisher, Waltham, MA [81] 
mouse anti-MAP2 antibody Millipore, Billerine, MA [92] 
mouse anti-TRH serum Raised in our laboratory [83, 84] 
rabbit anti- DAGLα serum Abcam, Cambdridge, UK [80] 
rabbit anti-CB1 serum Abcam, Cambdridge, UK [79] 
rabbit anti-MCT8 serum kind gift from Dr. TJ Visser, Rotterdam, The Netherlands [93] 
rabbit anti-nNOS serum Zymed Laboratorie, Waltham, MA [56] 
rabbit anti-sGCα1 serum Sigma Aldrich, St. Louis, MA [56] 
rabbit anti-UCN3 serum kind gift from Dr. WW Vale, La Jolle, CA [67] 
sheep anti-CB1 serum kind gift from Dr. M. Watanabe, Sapporo, Japan [77] 
sheep anti-histamine serum Raised in our laboratory [78, 84] 
sheep anti-NPY serum kind gift from Dr. I. Merchenthaler, Baltimore, MD [39, 94, 95] 
sheep anti-TRH serum Raised in our laboratory, #08W2, [67, 77, 83] 
sheep anti-α-MSH serum kind gift from Dr. JB Tatro, Boston, MA [96, 97] 
 Image analyzes of light microscopic preparations III.18
The sections were mounted on Superfrost slides (Thermofisher, Waltham, MA). Preparations 
developed with DAB and/or NiDAB developer were coverslipped with DPX mounting 
medium (Sigma Aldrich, St. Louis, MO), while the immunofluorescent preparations were 
mounted with the water-based Vectashield mounting medium (Vector Lab., Burlingame, CA) 
to prevent the fading of the fluorochromes and to avoid the shrinkage of the tissues.  
Light microscopic images were taken using a Zeiss AxioImager M1 microscope equipped with 
AxioCam MRc5 digital camera (Carl Zeiss Inc., Göttingen, Germany). 
Immunofluorescent sections were analyzed using a Radiance 2000 confocal microscope (Bio-
Rad Laboratories, Hemel Hempstead, UK) using the following laser excitation lines: 488 nm 
for FITC, 543 nm for Alexa 555 and dichroic/emission filters, 560 nm/500–530 nm for FITC 
and 570–590 nm for Alexa 555. The high magnification images were taken using 60x oil lens. 
These images represent a single optical section (less than 0.8 μm thick). For quantitative 
analyses, series of optical sections were recorded with 0.6 m Z steps. All labeled neurons 
were imaged in every forth section of the ARC or the TMN. 
Images were analyzed with Laser Vox (Bio Rad Laboratories, Hemel Hempstead, UK) and 
with Image pro plus software (Media Cybernetics Inc., Bethesda, MD). 
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The juxtapositions of immunolabeled axon varicosities and the target neurons were traced 
through the series of optical sections. A varicosity was considered to be juxtaposed to the 
target neuron if a visible gap was not seen by the observer between the two immunoreactive 
structures. The quantitative data of the TRH innervation of the histaminergic neurons was 
analyzed by one way ANOVA analyses followed by Newman Kuels post hoc test using 
STATISTICA 9 software (StatSoft Inc., Tulsa, OK) 
[86]. Data are presented as mean ± SEM.  
 Embedding, sectioning and examination of preparations for electron microscopic III.19
studies 
The sections immunostained for ultrastructural studies were osmicated using 1% osmium 
tetroxide in 0.1M PB for 30 min, and then treated with 2% uranyl acetate in 70% ethanol for 
30 min. Following dehydration in an ascending series of ethanol and propylene oxide, the 
sections were flat embedded in Durcupan ACM epoxy resin (Sigma-Aldrich, St. Louis, MO) 
on liquid release agent (Electron Microscopy Sciences, Fort Washington, PA)-coated slides, 
and polymerized at 56 °C for 2 days. Ultrathin 50–70 nm sections were cut with Leica ultracut 
UCT ultramicrotome (Leica Microsystems, Wetzlar, Germany), collected onto Formvar-
coated, single slot grids (Electron Microscopy Sciences, Fort Washington, PA), and examined 
with a JEOL electron microscope. 
 Specificity of antisera III.20
The specificity of the sheep anti-histamine serum [78], the sheep anti-TRH serum [67], rabbit 
anti-UCN3 serum [67], sheep anti-NPY serum [94] and sheep anti- α-MSH serum [8] was 
reported previously. Mouse anti-TRH serum was generated similarly to the sheep anti- TRH 
serum [67]. Briefly, the immunogenic complex was prepared by mixing 25 mg TRH (Bachem 
AG, Budendorf, Switzerland), 24 mg BSA (Sigma-Aldrich, St. Louis, MO), and 15 μL 
acrolein (Sigma-Aldrich, St. Louis, MO) in 4 mL PBS. The mixture was kept at room 
temperature overnight. The reaction was stopped by the addition of 10 mg sodium 
borohydride. Finally, the conjugate was dialyzed against PBS. For initial immunization, 250 
μg TRH-acrolein-BSA complexes in 100 μL PBS was emulsified with an equal volume of 
Freund’s complete adjuvant (Sigma-Aldrich, St. Louis, MO) and injected subcutaneously. 
Subsequent boosts with Freund’s incomplete adjuvant (Sigma-Aldrich, St. Louis, MO) were 
administered at 28 day intervals. The animals were decapitated 8 days after the third 
immunization and the serum was separated by centrifugation. The antiserum was affinity-
purified on a column loaded with TRH-coupled CNBr-activated Sepharose 4 Fast Flow gel 
(Amersham Pharmacia Biotech, Buckinghamshire, UK). Specificity of the antiserum for 
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immunocytochemistry was tested by preabsorption with TRH (Bachem, Bubendorf, 
Switzerland) at 80 μg/mL concentration, which resulted in the complete loss of 
immunostaining. Specificity of the antiserum was further verified by double-labeling of 
sections with the sheep anti-TRH (#08W2, ) serum and the well characterized rabbit anti-TRH 
no. 31 serum [98] which resulted in a complete colocalization of the two signals in axons as 
well as in cell bodies in colchicine-treated animals.  
To test the specificity of the anti-MCT8 antibody in the examined region, hypothalamic 
sections of MCT8-KO mice were used as a negative control (the MCT8-KO brain was kindly 
provided by Dr. H. Heuer, Jena, Germany). MCT8-immunoreactivity was completely absent 
in the median eminence of the MCT8-KO mice (Fig. 7D, E). The employed secondary 
antibodies were designed for multiple labeling and pre-absorbed by the producer with 
immunoglobulins of several species, including those in which the current non-corresponding 
primary antibodies were raised. Omission of any of the primary antisera from the multiple-
labeling immunofluorescence did not influence the pattern of the other immunoreaction 
signals. 
 Examination of the role of the endocannabinoid and NO transmitter systems in III.21
the mediation of the metabolic effects of NPY evoked in the PVN 
 Implantation of bilateral guide cannula in the PVN of mice III.21.1
A bilateral 26-gauge, 0.8 mm C/C stainless steel cannula (Plastics One, Roanoke, VA, USA) 
was stereotaxically implanted into the PVN under isoflurane anesthesia -0.8 mm posterior to 
bregma and to a depth of -4.8 mm from the surface of the brain, with bregma and lambda kept 
in the horizontal plane. The cannula was secured to the skull using dental acrylic cement, and 
then occluded with a dummy cannula. After a week of [67] recovery and demonstration that 
no loss of body weight was observed, correct placement of the cannula was verified by 
administration of NPY (0.25 nM/µl at 0.5 µl/min) using a 33-gauge stainless internal injector 
cannula. Mice that failed hyperphagic food intake (n=0) were removed from the study. 
 IntraPVN infusions in mice III.21.2
Peptides and reagents were dissolved in artificial cerebrospinal fluid (aCSF, prepared 
according to the instructions of Alzet, Cupertino, CA) and infused intraPVN (0.4 µl on each 
side) at a rate of 0.5 µl/min. Briefly, the bilateral internal cannula was connected to a 
polyethylene-50 tubing (Alzet, Cupertino, CA), the tubing connected to a 10 µl Hamilton 
syringe (Hamilton, Reno, NV) and the syringe was driven by a micro pump (KDS scientific, 
Holliston, MA). Once the internal injector cannula was in place, the animals were set lose 
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during the infusion (1 min) and the injector cannula maintained in place for another minute 
before replacing the animals in their cages. 
All animals were placed inside the calorimetric cage (TSE system, Frankfurt, Germany) 48 h 
before the experiment. Animals were kept under a 12 h light/dark cycle from 7.00 AM and 
housed in a temperature-controlled environment at 22.5 °C with free access to food and drink. 
Animals were customized daily to manipulation.  
Body mass composition (lean tissue mass, fat mass, free water and total water content) was 
analyzed using an Echo Medical systems’ EchoMRI (Whole Body Composition Analyzers, 
Houston, USA), according to manufacturer's instructions. Briefly, anesthetized mice were 
weighed before they were put in a mouse holder and inserted in EchoMRI analyzer. Readings 
of body composition were given within 3 mins. On the day of the metabolic measurements, at 
9.00 AM, appropriate intraPVN injections were performed within 4 mins (handling and 
injection), and the animals placed back into the calorimetric cage in the presence (ad libitum) 
or absence of food. Food was restored to the food restricted animals 7 h after the intraPVN 
injections. 
 Measurement of metabolic parameters III.21.3
In a first series of study, food of animals was removed 30 min before injection to prevent the 
confounding effects of the consumed food when the effect of intraPVN injections were 
investigated on parameters of energy homeostasis such as energy expenditure, estimation of 
basal metabolism, substrate utilization (RER) and locomotor activity. Reagent injection days 
were alternated with aCSF injection. (i.e.: day 1: aCSF, day 2: NPY, day 3 and 4: aCSF, day 5: 
NPY + AM251, day 6 and 7: aCSF, day 8: AM251).  
In a second, similar injection paradigm, food intake and spontaneous locomotor following 
intraPVN injections was investigated. Animals were placed in their cages with free access to 
regular chow. Food consumption, metabolic parameters and locomotor activities were 
recorded over 8 hours. Finally, caloric response, energy homeostasis and locomotor activity 
were investigated in animals subject to intraPVN injections of either aCSF or inhibitor N 
omega-propyl-L-arginine (NPLA)6 after an overnight fast. Food being replaced 15 min after 
the initial intraPVN injection. 
Mice were analyzed for whole energy expenditure (EE), oxygen consumption and carbon 
dioxide production, respiratory exchange rate (RER = VCO2/VO2, where V is a volume), and 
locomotor activity using calorimetric cages with bedding, food and water (Labmaster, TSE 
Systems GmbH, Bad Homburg, Germany). The ratio of gases was determined through an 
indirect open circuit calorimeter [99, 100]. This system monitors O2 and CO2 concentration 
                                                     
6
 selective nNOS inhibitor 
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by volume at the inlet ports of a tide cage through which a known flow of air is being 
ventilated (0.4 L/min), and compared regularly to a reference empty cage. The air sensors 
were calibrated with O2 and CO2 mixture of known concentrations (Air Liquide S.A., Paris, 
France). Oxygen consumption, carbon dioxide production and EE were recorded every 10 min 
for each animal during the entire experiment. Whole energy expenditure was calculated using 
the Weir equation respiratory gas exchange measurements [101]. Ambulatory movement was 
recorded using an infrared light beam-based activity monitoring system with online 
measurement at 100 Hz. 
Data analysis was performed using Microsoft Excel using extracted raw value of VO2 
consumed, VCO2 production (express in ml/h), and energy expenditure (Kcal/h). 
Subsequently, each value was normalized to whole lean tissue mass extracted from the 
EchoMRI analysis. 
 Estimation of basal metabolism III.21.4
No practical methods of estimation of the basal metabolism are available presently [102]. 
However, an estimation of basal metabolism was made on the following basis: the basal 
metabolic rate was calculated from the first experimental set when the animals did not have 
access to food to avoid confounding thermic effects of food. Data points of EE were 
considered to be the best estimation of basal metabolism when spontaneous activity during the 
previous 30 minutes was less than 1% of the highest daily value. 
 Statistical analysis of the in vivo data III.21.5
The results are expressed as mean ± SEM. Variance equality was analyzed by F test 
(Microsoft Excel), and comparisons between groups were carried out using Student’s t test or 
nonparametric Mann-Whitney-Wilcoxon’s test (Minitab, Paris, France). When appropriate, 
analyses of variances were performed followed either by a Bonferroni post hoc test with the 
appropriate parameters (drugs and time), and their interaction as factor (Minitab, Paris, 
France) a, b, c and d differed significantly (P<0.05).  Unless otherwise indicated in the text, a 
P-value of <0.05 was indicated by * and considered statistically significant. Data in the line 
figures are expressed as means ± SEM of at least 6 observations.  Bar graphs represent means 
± SEM obtained from ANOVA. For each phase, values (bars) without the same labels (a, b, c 
and d) differ significantly. 
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IV. Results 
 Presence of the NO system and effect of the NO system on the parvocellular part IV.1
of the PVN 
 Elucidation of the ultrastructural localization of the elements of the NO IV.1.1
transmitter system in the PVN. 
Our laboratory previously demonstrated the presence of CB1 receptor in both inhibitory and 
excitatory inputs of parvocellular neurons of the mouse PVN [52]. To determine whether NO 
also can function as a retrograde transmitter in the parvocellular part of the PVN, 
ultrastructural studies were performed in the periventricular and medial parvocellular parts of 
the PVN. The nNOS enzyme, the primary neuronal isoform of the NOS family [55] was 
observed in neuronal perikarya and dendrites (Fig. 3A-C) in addition to presynaptic terminals 
in the parvocellular part of the PVN (Fig. 3B-D). In many instances, silver grains denoting 
nNOS-immunoreactivity were closely associated with the postsynaptic density of both 
symmetric (Fig. 3C, D) and asymmetric type of synapses (Fig. 3A, B). Similarly, the alpha 1 
subunit of soluble guanylate cyclase (sGCα1), the primary receptor for NO, was also observed 
in presynaptic terminals (Fig. 3E, G) and postsynaptic (Fig. 3F, H) elements of both 
excitatory and inhibitory synapses (Fig. 3E-H). These data demonstrate that NO can function 
as both anterograde and retrograde transmitter in the parvocellular part of the PVN. 
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Figure 3 Ultrastructural localization of the components of the NO system in the parvocellular 
part of the PVN in mice.  
Electron micrographs illustrate the postsynaptic (A, C) and presynaptic (B, D) localization of 
nNOS-immunoreactivity in the parvocellular part of the PVN. The nNOS-immunoreactivity is 
labeled with highly electron dense gold–silver granules and observed in dendrites in the 
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proximity of both asymmetric (A, B) and symmetric (C, D) synapses. Soluble guanylyl-cyclase 
alpha 1 subunit-immunoreactivity (sGCα1) is present in presynaptic axons (E, G) and 
dendrites (F, H) in the PVN. sGCα1-immunoreactive (sGCα1-IR) is recognized by the 
presence of the electron dense silver granules in axon varicosities forming both symmetric (E) 
and asymmetric type synapses (G). Similarly, sGCα1-IR is seen in the proximity of 
postsynaptic density of both symmetric (F) and asymmetric (H) synapses. Arrows point to 
synapses. Scale bars=0.5μm. a= axon; d= dendrite; Nu= nucleus 
  
 Anatomical relationship of the endocannabinoid and NO systems in the PVN IV.1.2
To understand whether the endocannabinoid and NO systems regulate the very same neuronal 
inputs of the parvocellular neurons in the PVN, quadruple-labeling immunocytochemistry was 
performed using a microtubule-associated protein 2 (MAP2) neuronal marker combined with 
markers of glutamatergic or GABAergic terminals and components of the endocannabinoid 
and NO systems. In many instances, nNOS was present in dendrites of parvocellular neurons 
in the PVN close to the region where CB1-IR glutamatergic (vesicular glutamate transporter 1 
and 2 (VGLUT1 and VGLUT2)-IR; Fig. 4A1,-B2) or GABAergic (vesicular inhibitory amino 
acid transporter (VIAAT)-IR; Fig. 4C1, C2) terminals form juxtapositions with dendrites. In 
addition, the endocannabinoid 2-AG synthesizing enzyme, the DAGLα, was observed to 
colocalize with nNOS in dendrites of parvocellular neurons (Fig. 4D1-D2).  
To further support the anatomical basis of an interaction between the two retrograde 
transmitter systems, ultrastructural studies were performed, showing that nNOS is present in 
close proximity to the postsynaptic site of the synapse of some CB1-IR glutamatergic and 
GABAergic terminals (Fig. 4E, F). These data suggest that the two retrograde transmitter 
systems may interact in the regulation of the inputs of the parvocellular neurons. 
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Figure 4 Association of the endocannabinoid and NO systems with the same synapses of 
parvocellular neurons in the PVN.  
Images of quadruple immunolabeling (A-C) preparations illustrate the close association of 
cannabinoid type 1 receptor (CB1)- immunoreactive (IR) excitatory (A, B) and inhibitory (C) 
axon varicosities to neuronal nitric oxide synthase (nNOS) containing dendrites in the 
parvocellular part of the PVN. The axon varicosities of excitatory neurons are labeled with 
vesicular glutamate transporter 1 (VGLUT1) (A1, green) or vesicular glutamate transporter 2 
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(VGLUT2) (B1, green)-immunoreactivity, while the inhibitory terminals are labeled with 
vesicular inhibitory amino acid transporter (VIAAT)-immunoreactivity (C1, green). The 
dendrites are visualized based on their microtubule-associated protein 2 (MAP2)-
immunoreactivity (A-C, blue). CB1-immunoreactivity is labeled with red fluorescence, while 
the nNOS-immunoreactivity is pseudocolored white. For better visualization, the MAP2 and 
CB1-immunoreactivities in the same field are also shown separately (A2-C2). Images of 
triple-labeled immunofluorescent preparations (D) show the colocalization (arrows) of the 
endocannabinoid synthesizing diacylglycerol lipase alpha (DAGLα) (red) and nNOS (white) 
in the dendrites (MAP2-IR, blue) of the parvocellular part of the PVN. For better 
visualization, the MAP2 and CB1-immunoreactivities in the same field are also shown 
separately (D2). Electron micrographs illustrate synaptic associations (arrows) between a 
nNOS-IR dendrite (E) and perikaryon (F) with CB1-IR axon terminals. The nNOS-IR elements 
are labeled with highly electron dense gold–silver granules, while the CB1-IR terminals are 
recognized by the presence of the electron dense nickel-diaminobenzidine (NiDAB) 
chromogen. The associations of the two retrograde transmitter systems can be observed in 
both asymmetric (E) and symmetric (F) type of synapses in the parvocellular part of the PVN 
in mice. Arrows point to the synapses. Scale bars = 2μm on (A-C), 10μm on (D) and 0.5μm on 
(E, F). Nu= nucleus 
 
 Examination of the role of the endocannabinoid and the NO systems of the PVN IV.1.3
in the mediation of the NPY induced regulation of energy homeostasis 
To determine the role of the two retrograde transmitter systems in the mediation of the various 
actions of NPY on the energy balance within the PVN, we studied whether local 
administration of inhibitors of the endocannabinoid and NO systems influence the effects of 
NPY on food intake, energy expenditure, substrate utilization and locomotor activity. NPY 
administration into the PVN (intraPVN) impacted on whole energy expenditure, spontaneous 
activity and respiratory exchange ratio (RER) with a characteristic biphasic pattern if the 
animals had no access to food (Fig. 5F), in good agreement with previous observations by 
Ruffin et al [103]. The biphasic response being prototypical of NPY-initiated response, the 
two phases were independently analyzed. Therefore, the experiments were split into two main 
periods, 0-2.5h and 2.5-7h, after which food was given to the mice at 7 h.  
The first 2.5 h after intraPVN NPY injection was characterized by a slight increase in energy 
expenditure (P<0.01; Fig. 5A, B) primarily assignable to increased locomotor activity 
(P<0.001; Fig. 5C, D). The treatment also increased the carbohydrate utilization evidenced by 
the increase of RER (P<0.001; Fig. 5E, F) compared to aCSF administration. The second 
phase post injection (2.5h-7h) was characterized by a significant decrease in energy 
expenditure (Fig. 5A, B) and a normalization of both locomotor activity and substrate 
utilization compared to aCSF treated animals (Fig. 5C, D, E, F). These changes persisted until 
food was reintroduced to the animals at 7h.  
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Fasting is typically associated with sustained increase in NPY release from ARC neurons to 
PVN structures and associated with a transient increase in foraging behavior (after an 
overnight fast) followed by a drastic decrease in activity as a means to conserve energy [104]. 
A similar change in locomotor activity also occurs in food restricted animals before the time 
of anticipated feeding when the NPY release is increased in the PVN [105, 106].  
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Figure 5 Effect of intraPVN co-administration of NPY with the CB1 antagonist, AM251, or 
the nNOS inhibitor, NPLA, on parameters of energy expenditure.  
Effect of intraPVN co-administration of NPY and AM251 on energy expenditure normalized 
by total lean body mass (A), spontaneous locomotor activity (C), and respiratory exchange 
ratio (RER) (E) of n=7-9 mice with no access to food. Effect of intraPVN co-administration of 
NPY and NPLA on energy expenditure normalized by total lean body mass (B), spontaneous 
locomotor activity (D), and respiratory exchange ratio (RER) (F) of n=7-9 mice with no 
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access to food. Estimation of the resting metabolism of mice injected with NPY alone or co-
administrated with AM251 or NPLA (G), 27, 26, 28 and 28 points were collected respectively 
for aCSF, NPY, NPY-AM251 and NPY-NPLA treated groups within the second phase 
(between 2.5 h and 7 h, grey area). Each group was injected either with aCSF (grey), NPY 
(black), NPY+AM251 (red), NPY+NPLA (blue) at T=0, and food was replaced at T=7 h. Bar 
graphs were calculated from the ANOVA analysis for each phase. Data with different 
superscript letters are significantly different (P<0.05) according to the ANOVA analysis 
followed by a Bonferroni post hoc test. Data are expressed as mean ± SEM. 
 
Intra PVN NPY administration seems to recapitulate these behavior outputs in the presence or 
absence of food (Fig. 6).  
Local administration of the selective nNOS NPLA resulted in an extended period of increase 
in locomotor activity (Fig. 5D). Antagonizing CB1 signaling pathway through local AM251 
administration did not oppose NPY action on locomotor activity, neither in the first nor in the 
second period (Fig. 5C), but resulted in a significant change in substrate utilization as shown 
by attenuation of the NPY-induced increase in RER during the first, hyperactive period (Fig. 
5E). NPLA administration, however, did not affect RER in either period (Fig. 5F).  
Importantly, between 2.5h and 7h, both AM251 and NPLA treatments partially reversed the 
decrease in energy expenditure induced by NPY (Fig. 5A, B). However, the action of NPLA 
on the NPY-mediated inhibition of energy expenditure could be attributed to the extended 
hyperactivity (Fig. 5B). In contrast, the effect of AM251 on the energy expenditure was not 
associated with change in locomotor activity (Fig. 5C), suggesting that resting energy 
expenditure might account for this effect. Therefore, resting energy expenditure was 
calculated during the 2.5-7h period, showing that while AM251 markedly attenuated the 
inhibitory effect of NPY on resting energy expenditure, NPLA treatment had no effect on this 
parameter (Fig. 5G). 
In a separate set of experiments, the involvement of the two retrograde signaling pathways in 
the mediation of the acute NPY-mediated food intake was investigated. IntraPVN NPY 
administration resulted in a more than 5-fold increase in food intake and 2-fold increase in 
locomotor activity during the first 2.5 hours (Fig. 6B). Although intraPVN administration of 
the endocannabinoid antagonist, AM251, alone, or in combination with NPY had a marginal 
effect on food intake and locomotor activity (Fig. 6B), the inhibition of nNOS signaling within 
the PVN completely prevented the NPY-induced increase in food intake and locomotor 
activity (Fig. 6A, B), while administration of NPLA, alone, had no effect (Fig. 6C).  
As exogenously administered NPY increased the NPY concentration in the PVN before food 
was provided in our experimental paradigm, and fasted animals also have increased NPY 
concentration in the PVN before they receive food, we tested whether inhibition of NO 
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signaling within the PVN can influence the behavior of fasted and refed mice. IntraPVN 
administration of nNOS markedly decreased the food intake   in animals refed after fasting, 
indicating that the endogenously released NPY also utilizes NO to influence this parameter of 
energy homeostasis (Fig. 6C). 
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Figure 6 Food intake (A) and spontaneous activity (B) of mice injected intraPVN with aCSF 
(grey), NPY (black) alone, co-administrated with AM251 (red) or NPLA (blue).  
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Food intake and spontaneous locomotor activity was monitored over 8 hours post injection. 
IntraPVN injection of NPLA (light blue) diminished food intake following an overnight fast 
(C). Mean ± SEM extracted from the analysis of variance of food intake and spontaneous 
locomotor activity are represented in the bar graphs. Data with different superscripts letters 
are significantly different (P<0.05) according to the ANOVA followed by Bonferroni post hoc 
test. Data are expressed as mean ± SEM. n = minimum 6 mice per group. 
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 Identification of the presence of MCT8 thyroid hormone transmitter in the axon IV.2
terminals of the hypophysiotropic TRH neurons. 
In the ME, intense and diffuse MCT8-immunoreactivity was observed in cell bodies and 
processes exhibiting the characteristic distribution and morphology of tanycytes (Fig. 7A, B). 
In addition, punctate MCT8-immunoreactivity was detected among the tanycyte processes in 
the external zone of the ME (Fig. 7C). The specificity of the immunostaining was 
demonstrated by the absence of immunostaining in MCT8 KO mice (Fig. 7D, E). 
Ultrastructural analysis of the MCT8-IR elements in the external zone of the ME demonstrated 
strong MCT8-immunoreactivity distributed uniformly in the tanycyte processes (Fig. 8A). In 
addition, MCT8-immunoreactivity was also observed in axon terminals, where the silver 
grains focally accumulated in a segment of the axon varicosities in close proximity to the 
plasma membrane (Fig. 8B, C).  
Double-labeling immunofluorescent staining for MCT8 and TRH demonstrated the presence 
of MCT8-immunoreactive puncta on the surface of the vast majority of TRH-containing axon 
varicosities in the external zone of the ME (Fig. 9) 
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Figure 7 MCT8 immunoreactivity in the rodent mediobasal hypothalamus.  
Low magnification photograph illustrates the presence of monocarboxylate transporter 8 
(MCT8)-immunoreactivity associated with tanycytes (A). In the ME, strong MCT8-
immunoreactivity is observed in tanycyte processes (B, arrows). In addition to occurring in 
tanycyte processes (arrows), MCT8-immunoreactivity is also observed in small dot like 
structures reminiscent of axon varicosities (arrow heads) (C). MCT8 immunoreactivity in the 
mediobasal hypothalamus of wild-type (D) and MCT8-KO mice (E). III, third ventricle; Scale 
bars: 200 µm in A, 100 µm in B, 20 µm in C, 50 µm in D, E. 
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Figure 8 Ultrastructure of MCT8 immunoreactive structures in the rat ME. 
Monocarboxylate transporter 8 (MCT8)-immunoreactivity (silver grains) is associated with 
tanycyte (A) and axon varicosities (B, C) in the external zone of the median eminence (ME). In 
the axon varicosities, silver grains accumulate in a small region of the varicosity close to the 
cytoplasmic membrane (B, C). Scale bar: 500 nM. 
 
 
Figure 9 MCT8 immunoreactivity in axon varicosities of the rat hypophysiotropic TRH 
neurons.  
The immunofluorescent signal for monocarboxylate transporter 8 (MCT8) (red) is distributed 
as small dots throughout the external zone of median eminence and appears (arrowheads) on 
the surface of thyrotropin-releasing hormone (TRH) immunofluorescent axon varicosities 
(green). Scale bar: 2 µm 
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 TRH/UCN3 neurons of the perifornical area/BNST region innervate the POMC IV.3
neurons of the ARC 
Since our laboratory has demonstrated that the vast majority of the neurons co-synthesizing 
TRH and UCN3 are located in continuous neuronal group located in the perifornical area and 
in the BNST [67], the colocalization of TRH and UCN3 was used as a marker of axons 
originating from the TRH/UCN3 neurons of the perifornical area/BNST region. Within the 
ARC, UCN3-IR axons were primarily observed in the lateral part of the nucleus, while a dense 
network of TRH-IR axons was observed throughout the entire ARC. The vast majority of 
UCN3–IR axons contained TRH-immunoreactivity in this nucleus. However, a large portion 
of TRH-IR axons did not contain UCN3. Double-labeled TRH/UCN3 axons were primarily 
located in the lateral part of the ARC (Fig. 10).  
NPY-IR neurons were predominantly localized in the ventromedial part of the ARC where 
only scattered TRH/UCN3 axons were found (Fig. 11). TRH/UCN3-IR axon terminals were 
observed in juxtaposition to only 4.3±1.3% of NPY-IR neurons. An average of 1.7±0.2 
TRH/UCN3 axon varicosities were observed on the surface of the contacted NPY neurons. 
The localization of the α-MSH-containing neurons in the ARC, however, overlapped with the 
distribution of the double-labeled TRH/UCN3-IR axons in the lateral ARC (Fig. 12A, C, E). 
More than a half (52.38±8.5%) of the α-MSH-containing neurons was contacted by 
TRH/UCN3-IR axon terminals. The average number of TRH/UCN3 axon varicosities was 
6.48±0.82 on the contacted α-MSH neuron.  
Since the vast majority (88.1±1.2%) of UCN3-IR axon varicosities on the surface of α-MSH-
IR neurons also co-contained TRH-immunoreactivity, UCN3-immunoreactivity was used for 
ultrastructural studies to label the UCN3 axons of perifornical area/BNST region origin.  
UCN3-IR axon terminals labeled with nickel-intensified diaminobenzidine (NiDAB) formed 
synaptic contacts with the silver-intensified immunogold-labeled α-MSH-IR perikarya and 
dendrites (Fig. 12G, H). All observed synapses between these two systems were the 
asymmetric type.  
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Figure 10 UCN3-IR (green) and TRH-IR (red) innervation of the ARC in the rat.  
Thyrotropin-releasing hormone (TRH) - immunoreactive (IR) axons densely innervate the 
entire arcuate nucleus (ARC), while double-labeled.Urocortin3 (UCN3)/TRH axons are 
concentrated in the lateral part of the nucleus, while only scattered double-labeled axons 
reside in the medial part of the ARC. III, third ventricle, Scale bar: 50 µM 
 
Figure 11 Relationship of TRH/UCN3- containing axons on the NPY neurons in the ARC. 
Triple-labeled immunofluorescent detection of the urocortin 3 (UCN3) - (green), thyrotropin-
releasing-hormone-immunoreactive (TRH-IR) (red) axons and neuropeptide Y (NPY) - (blue) 
neurons in the arcuate nucleus (ARC). Only scattered double-labeled axons can be observed 
around the NPY neurons in ventromedial part of the ARC. Scale bar on (A) = 10 μm 
III 
TRH/UCN3 
Lateral part 
Medial part 
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Figure 12 Relationship of TRH/UCN3- containing axons and the α-MSH neurons in the ARC.  
Triple-labeled immunofluorescent detection of the urocortin 3 (UCN3) - (green), thyrotropin-
releasing-hormone-immunoreactive (TRH-IR) (red) axons and alpha-melanocyte-stimulating 
hormone (α-MSH) - (blue) neurons in the arcuate nucleus (ARC). The TRH/UCN3 axons 
contacted more than half of the α-MSH neurons (A-F) in the lateral part of ARC. Arrows point 
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to the double-labeled axon varicosities on the surface of α-MSH neurons (A-F). (A), (C) and 
(E) represent projections of 24 (A) or 8 (C and E) 0.8µm thick optical slices, while (B), (D) 
and (F) show a single 0.8 µm thick optical slice. Electron micrographs (G, H) illustrate 
synaptic associations (arrows) between α-MSH-IR neurons and UCN3-IR terminals in the 
ARC. The α-MSH -IR perikaryon (C) and dendrite (D) are labeled with highly electron dense 
gold–silver granules, while the UCN3-IR terminals are recognized by the presence of the 
electron dense diaminobenzidine chromogen. Asymmetric types of synapses were observed 
between UCN3-IR axon varicosities and the α-MSH-IR profiles. Arrows (G, H) point to the 
synapses. Nu, nucleus; Scale bar on (F) = 10 μm and corresponds to (A-E), (H) = 0.25 μm 
and corresponds to (G). 
 
 Relationship between TRH-IR axons and histaminergic neurons in the subnuclei IV.4
of the TMN 
Histamine-IR perikarya and dendrites were observed exclusively in the TMN, as it was 
previously described [107, 108]. Large, multipolar histamine-IR neurons were distributed in 
all five subnuclei (E1-5) of the TMN, forming the largest cell cluster in the E2 subnucleus 
close to the lateral surface of the hypothalamus (Fig. 13-15). Perikarya of the histamine-IR 
neurons in the E1 and E2 subnuclei were densely clustered, while the histamine-IR neurons in 
the E3-E5 subnuclei were more loosely organized (Fig. 13-15). TRH-IR neurons were also 
observed in the TMN, but almost exclusively in the E4 subnucleus (Fig. 13-15). Compared to 
the number of histamine-IR neurons in this subdivision, however, TRH neurons were far less 
abundant. Only scattered TRH-IR neurons were observed in the E1-E3 and E5 subnuclei. 
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Figure 13 Distribution of the TRH-IR elements (black) and the histamine-IR neurons (brown) 
in the subnuclei of the TMN in four different rostrocaudal levels of the TMN. 
The localization of the 5 subnuclei of the tuberomammillary nucleus (TMN) (E1-5) are labeled 
on the images. MR, mammillary recess; Scale bar = 500 μm. 
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Figure 14 Relationship of the TRH-IR (black) axon varicosities and the histamine-IR neurons 
(brown) in the 5 subnuclei of the TMN (E1-5).  
Arrows point to thyrotropin-releasing-hormone-immunoreactive (TRH-IR) axon varicosities in 
juxtaposition to histamine-IR neurons. Especially high numbers of TRH-IR axons were 
observed in contact with the histamine-IR neurons in the E4 subnucleus (D). Scale bar = 20 
μm. 
 
TRH-IR axons were found in all five subnuclei of the TMN, but the densest network of TRH-
IR axons was observed in the E4 subnucleus (Fig. 13, 14, 15). Quantitative analyses of the 
morphological interaction of TRH-IR varicosities and histamine-IR neurons in the subnuclei 
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of the TMN was performed on confocal microscopic Z-stacks of less than 1 µm thick optical 
slices of double-labeled fluorescent sections (Fig. 15)  
 
 
Figure 15 TRH-IR (red) boutons innervate the histamine-IR neurons (green) (arrows) in the 
TMN.  
High power, confocal microscopic images of immunofluorescent preparations illustrate the 
juxtaposition of the thyrotropin-releasing hormone-immunoreactive (TRH-IR) varicosities and 
the histamine-IR neurons in the five subnuclei of the tuberomammillary nucleus (TMN) (E1-5). 
Arrows point to TRH-IR axon varicosities in juxtaposition to histamine-IR neurons. Images 
represent single optical sections with less than 0.8μm thickness. Scale bar = 20 μm. 
The results of the analyses are summarized in Table 6. TRH-IR axon varicosities were 
observed on the surface of all histamine-IR neurons in the E4 subnucleus. An average of 
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27.0±1.2 varicosities per histamine-IR neurons were counted in this subnucleus (Fig. 15D). 
Similarly, all histamine-IR neurons were contacted by TRH-IR axon varicosities in the E5 
subnucleus (Fig. 15E), but fewer TRH-IR varicosities (P<0.001) were observed on the surface 
of these cells (7.9±0.5). A dense TRH-IR innervation of E2 and E3 subnuclei (Fig. 15B, C) 
was observed, but somewhat fewer (P<0.001) histamine-IR neurons appeared to be contacted 
in these subnuclei; 93.9±0.9% in E2 and 92.1±1.3% in E3, averaging 6.3±0.2 and 6.8±0.2 
TRH-IR varicosities per histamine-IR neuron in each subnucleus, respectively. A less frequent 
interaction between TRH-containing axon terminals and histamine-IR neurons was observed 
in the E1 subnucleus (Fig. 14A, 15A), where only 85.7±0.9% of the histamine-IR neurons 
(significantly less than all other groups P<0.001) were contacted by an average of 4.0±0.2 
TRH-IR axon varicosities/innervated cells (significantly less than in all other groups P<0.001). 
At ultrastructural level, TRH-IR nerve terminals, labeled with electron dense DAB reaction 
product, were observed to established membrane appositions with histamine-IR perikarya and 
dendrites, recognized by the presence of highly electron dense immunogold-silver particles 
distributed throughout the labeled structures (Fig. 16). The juxtaposed TRH-IR terminals and 
histamine-IR neurons were tracked through series of ultrathin sections. Both asymmetric type 
(Fig. 16A, B, F, G) and symmetric type (Fig. 16C, D, E, H) synaptic specializations were 
observed on both perikarya and dendrites of histamine-synthesizing neurons. Analysis of 56 
synapses between histamine neurons and TRH-IR terminals revealed 35 asymmetric and 14 
symmetric type synaptic associations. For 7 of the identified synapses, the specific type could 
not be unequivocally determined. 
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Figure 16 Electron micrographs show synaptic associations (arrows) between histamine- IR 
neurons and TRH-IR terminals in the TMN.  
The histamine- immunoreactive (IR) perikarya and dendrites are labeled with highly electron 
dense gold–silver granules, while the thyrotropin-releasing hormone (TRH)-IR terminals are 
recognized by the presence of the electron dense diaminobenzidine (DAB) chromogen. 
Medium-power image illustrates an asymmetric type synapse established between a TRH-IR 
axon varicosity and a histamine-IR perikaryon (A) shown in greater detail in (B). A symmetric 
type axosomatic synapse is shown in (C, D). High-power magnification images show 
asymmetric (F, G) and symmetric (E, H) axodendritic synapses between TRH and histamine-
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IR structures. Arrows point to the synapses. HIS, histamine-IR structure; Nu, nucleus; TRH, 
TRH-IR structure; Scale bars=0.1 μm in (B, D-H); 1 μm in (A, C). 
Table 6 Quantitative analysis of the juxtaposition of TRH-IR axon varicosities and histamine-
IR neurons in the 5 TMN (E1-5). 
 
E1 E2 E3 E4 E5 
Percentage of histamine- 
IR neurons contacted by 
TRH-IR axons 
85.7±0.9 
a 
93.9±0.9 
b 
92.1±1.3 
c 
100.0±0.0 
d 
100.0±0.0 
d 
Number of TRH 
varicosities/histamine- 
IR neuron 
4.0±0.2 
a 
6.3±0.2 
e 
6.8±0.2 
e 
27.0±1.8 
f 
7.9±0.5 
e 
a significantly different from E2, E3, E4, E5; b significantly different from E1, E3, E4, E5 
c significantly different from E1, E2, E4, E5; d significantly different from E1, E2, E3 
e significantly different from E1, E4; f significantly different from E1, E2, E3, E5; P<0.05 
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V. Discussion 
 Anatomy of the NO system in the parvocellular part of the PVN and its potential V.1
interaction with the endocannabinoid system 
NPY is one of the most potent orexigenic molecules known, its effects on energy expenditure 
and food intake are at least in part mediated in the PVN [3]. During fasting, when the hunger 
drive is increased, the NPY level is also increased in the PVN, and administration of NPY 
directly into this nucleus of sated rats markedly increases food intake and decreases energy 
expenditure [109]. However, little information is available about how NPY exerts these effects 
on energy homeostasis within the PVN. Electrophysiological data from our laboratory [49] 
demonstrated that retrograde signaling systems are involved in the mediation of the NPY 
effects within the PVN. One of the retrograde signaling systems involved in this process is the 
endocannabinoid system [49]. Since the interaction of the endocannabinoid and the NO 
system was demonstrated in the regulation of hippocampal axon terminals [57], we have 
studied whether the NO may also serve as retrograde transmitter in the PVN.  
By ultrastructural studies, we demonstrated that both nNOS and the major NO receptor, 
sGCα1, is present in both pre- and postsynaptic sites within the parvocellular subdivisions of 
the PVN. In many instances, the nNOS-immunoreactivity was associated to the postsynaptic 
density of synapses. These data indicate that similarly as it was described in the hippocampus 
[56], NO may have both anterograde and retrograde transmitter function. Later, 
electrophysiological data from our laboratory supported this finding. It was shown that 
inhibition of nNOS completely prevented the inhibitory effect of NPY on the inhibitory inputs 
of the parvocellular neurons, but alone had no effect on the excitatory inputs of the 
parvocellular neurons [49]. 
As electrophysiological data from our laboratory showed that inhibition of either the 
endocannabinoid or the NO system completely prevented the effect of NPY on the inhibitory 
inputs [49], we hypothesized that the two systems regulate the very same synapses. Therefore, 
we have studied whether the elements of the two systems are associated to the same synapses 
in the parvocellular part of the PVN.  
Our quadruple-labeling immunofluorescent data showed that both glutamatergic and 
GABAergic CB1-containing axon varicosities juxtapose to nNOS-containing dendrites of the 
parvocellular neurons in the PVN. In addition, the co-localization of nNOS and the 
endocannabinoid-synthesizing DAGLα was observed in the dendrites of the parvocellular 
neurons. These data further suggested the interaction of the two signaling systems in the 
regulation of the very same synapses of the parvocellular neurons. Since light microscopy 
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cannot prove that the juxtaposed profiles form synaptic associations, we have studied the 
association of the two systems at ultrastructural level. Using electron microscopy, we have 
found that in many cases nNOS-immunoreactivity was associated to the postsynaptic side of 
the synapse formed by a CB1-containing axon varicosity. This type of arrangement of nNOS 
and CB1 was observed in association to both symmetric and asymmetric type synapses 
suggesting that the two signaling systems may interact not only in the regulation of the 
inhibitory, but also in the regulation of the excitatory synapses of the parvocellular neurons of 
the PVN. Since inhibition of endocannabinoid system alone prevented the effect of NPY on 
the excitatory input of parvocellular neurons, but inhibition of nNOS alone had not effect on 
these inputs, to test the potential interaction of the two signaling systems in the excitatory 
synapses of the parvocellular neurons, our laboratory studied whether co-administration of the 
subthreshold doses of the CB1 antagonist AM251 and the nNOS inhibitor together can inhibit 
the effect of NPY on the excitatory synapses of parvocellular neurons. The results of this 
electrophysiological experiments showed that co-administration of subthreshold dose of 
AM251 and NPLA completely prevented the NPY induced inhibition of the excitatory inputs 
of the parvocellular neurons proving the functional interaction of the two signaling systems in 
the excitatory synapses.  
Thus our morphological data demonstrate that the NO system is utilized as both anterograde 
and retrograde transmitter within the parvocellular part of the PVN and regulates both 
excitatory and inhibitory connections in this brain region. Furthermore, our data demonstrate 
the anatomical basis of the interaction of the NO and endocannabinoid systems in the 
regulation of the inputs of the parvocellular PVN neurons. The functional importance of these 
findings was demonstrated by the patch clamp electrophysiological observations of our 
laboratory. 
 The endocannabinoid and the NO systems of the PVN mediate different effects of V.2
NPY on the energy homeostasis 
To determine the importance of the endocannabinoid and NO systems of the PVN in the 
mediation of NPY induced changes of the energy homeostasis, in vivo experiments were 
performed. Inhibition of nNOS within the PVN completely prevented the potent stimulatory 
effect of the intraPVN administration of NPY on the food intake. Furthermore, inhibition of 
nNOS decreased food intake even if NPY was not administered exogenously, but the 
endogenous NPY release was increased in fasted animals within the PVN before food was 
reintroduced. These data strongly suggest an important role for NO in the regulation of food 
intake, but only in the presence of increased release of NPY in the PVN. In addition, 
antagonizing nNOS with NPLA prolonged the stimulatory effects of NPY on locomotor 
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activity without influencing the RER. Since the NPY-induced increase in RER paralleled the 
NPY-induced increase in locomotor activity, it raised the possibility that the NPY-induced 
increase in carbohydrate utilization was induced by increased locomotor activity and not a 
direct, central effect of NPY. However, NPLA treatment only prolonged the NPY-induced 
increase in locomotor activity without influencing substrate utilization, suggesting that the 
effects of NPY on locomotor activity and substrate utilization are mediated via separate, 
central mechanisms within the PVN.  
In contrast, antagonizing the endocannabinoid signaling system had no effect on food intake, 
as demonstrated by the absence of a response when a CB1 antagonist was administered 
simultaneously with NPY directly into the PVN, or during fasting. Nevertheless, 
endocannabinoid signaling would appear to be involved in the mediation of the NPY-induced 
effect on energy expenditure, as inhibition of CB1 prevented ~50% of the NPY-induced 
decrease in energy expenditure. This observation is similar to the effect of NPY on 
glutamatergic synapses, which can be blocked by AM251 but not by NPLA. Therefore, we 
hypothesize that NPY inhibits energy expenditure via inhibition of the excitatory inputs of the 
parvocellular neurons.  
In contrast to the endocannabinoid system, NO is utilized as both a retrograde and anterograde 
transmitter in the PVN. While the nature of patch clamp methodology allowed the 
examination of NO as retrograde transmitter, in vivo inhibition of nNOS in the PVN blocked 
both anterograde and retrograde NO transmission. Since all of the retrograde transmitter 
mediated effects of NPY could be also prevented in patch clamp studies with administration of 
the CB1 antagonist AM251, but the in vivo effects of NPY on the food intake [49] and 
locomotor activity were influenced only by local inhibition of NO signaling within the PVN, 
we hypothesize that the effects of NPY on food intake and locomotor activity are mediated by 
local neuronal circuits utilizing NO as an anterograde transmitter.  
Interestingly, inhibition of the NO synthesis in the PVN had different effects on NPY-induced 
locomotor activity in the presence or absence of food. When food was not available, NPLA 
prolonged the NPY-induced increase in locomotor activity, while in the presence of food; 
NPLA completely blocked NPY-induced locomotor activity. Therefore, it is likely that NPY 
stimulates locomotor activity via different mechanisms in the presence or absence of food. 
Thus our data demonstrate that the endocannabinoid system is involved in the mediation of the 
effects of NPY on the energy expenditure, while the NO system is involved in the regulation 
of food intake by NPY. In addition, the presented data indicate that the effect of NPY on the 
locomotor activity, RER, food intake and energy expenditure are mediated by different 
neuronal circuits of the PVN. 
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 Presence of the MCT8 protein in axon terminals of the hypophysiotropic TRH V.3
axons in the ME of the rat  
MCT8 is considered to be the predominant, neuronal T3 transporter, and mutations of this 
gene in humans are characterized by a severe neurologic phenotype [62]. Importantly, absence 
of functional MCT8 also results in increase of circulating thyroid hormone levels in both 
humans and rodents [62, 64] indicating the importance of MCT8 in the feedback regulation of 
the HPT axis. We demonstrated that in the median eminence, MCT8 is present not only in the 
tanycytes, but also in the hypophysiotropic axon terminals. Using double-labeling 
immunofluorescence, we showed that among these hypophysiotropic terminals, specifically 
the axon terminals of the hypophysiotropic TRH neurons also contain MCT8. As the transport 
of T3 through the blood-brain-barrier is not efficient and T4 cannot bind to the nuclear thyroid 
hormone receptors [27], local thyroid hormone activation is necessary for the feedback 
regulation of the thyroid hormones. As axon terminals of the hypophysiotropic TRH neurons 
in the external zone of the ME lie in close proximity to the endfeet processes D2 expressing 
tanycytes [110] the observation that practically all hypophysiotropic axon terminals in the ME 
express MCT8 indicate that T3 released from tanycytes could readily accumulate in the 
terminals of hypophysiotropic TRH neurons and then reach the nucleus of these cells by 
retrograde transport. Although the machinery driving the retrograde transport of T3 is yet 
unknown, fast retrograde axonal transport of biologically active molecules is not 
unprecedented [111]. Since the perikarya of the hypophysiotropic TRH neurons are located 
relatively far from the tanycytes, it is likely that the retrograde axonal transport of T3 is the 
main route of T3 trafficking between tanycytes and hypophysiotropic TRH perikarya.  
T3 in the ME originates from two sources: from the peripheral circulation and from the 
tanycytes. The ME is located outside of the blood-brain-barrier [26], thus, T3 can enter freely 
to the extracellular space of the ME from the fenestrated capillaries of the hypophyseal portal 
circulation [26]. In addition, tanycytes can take up T4 from the CSF, from the blood stream or 
from the extracellular space of the median eminence [112]. As tanycytes express D2, this 
enzyme can activate the T4 by converting it to the active T3 and release this hormone to the 
ME [27]. The changes of peripheral thyroid hormone levels do not regulate the activity of D2 
in the tanycytes [113], therefore, under basal conditions tanycytes simply convert the changes 
of peripheral T4 concentration to changes of median eminence T3 concentration. Under 
certain physiological and pathophysiological conditions, however, the D2 activity of tanycytes 
is regulated. For example, in response to the administration of bacterial lipopolysaccharide 
(LPS), a model of infection, the D2 activity of tanycytes is markedly increased independently 
from the changes of circulating thyroid hormone levels [114, 115], inducing local 
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hypothyroidism in the ARC-ME region [116]. This local increase of T3 concentration is 
necessary for the development of infection induced central inhibition of the HPT axis [117]. 
Thus the involvements of tanycytes in the feedback regulation of the hypophysiotropic TRH 
neurons provide an additional regulatory element in the central control of the HPT axis [117].  
Thus, the identification of MCT8 in the axon terminals of the HPT axis resulted in the 
development of a novel model of the feedback regulation of the HPT axis [27] that can answer 
several earlier unresolved questions. For example, it was unclear earlier, why the circulating 
thyroid hormone levels of the D2 KO mice are normal or why the non-hypophysiotropic TRH 
neurons are not responsive to the changes of peripheral thyroid hormone levels despite the fact 
that these cells also contain thyroid hormone receptors [27]. 
Thyroid hormone also plays a critical role in the regulation of other neuroendocrine axes 
including, the reproductive axis, adrenal axis and growth-hormone (GH) secretion [118-123]. 
The observation that practically all hypophysiotropic axon terminals in the ME express MCT8 
indicates the ME can be the main source of T3 that regulates these hypophysiotropic axes. 
Indeed, tanycytes are known to regulate the hypophysiotropic GnRH neurons via modulation 
of T3 availability in seasonal animals [124]. 
  TRH/UCN3 neurons of the perifornical area/BNST region innervate the α-MSH V.4
neurons of the ARC 
Previous data from our laboratory demonstrated that TRH and UCN3 are co-synthetized in the 
neurons located in the perifornical area/BNST region [67]. To determine whether TRH/UCN3 
neurons may regulate food intake via orexigenic and/or anorexigenic neurons in the ARC, the 
relationship between double-labeled TRH/UCN3 axons and the NPY or α-MSH neurons was 
studied in the ARC using triple-labeling immunofluorescence. The double-labeled axons 
contacted only a minority of NPY neurons, making it unlikely that TRH/UCN3 neurons have a 
major, direct influence on this orexigenic neuron population. In contrast, more than half of the 
anorexigenic POMC were contacted by multiple TRH/UCN3 axon varicosities. Since the vast 
majority of UCN3 axons also contained TRH in the ARC, we used UCN3 as a marker of 
TRH/UCN3 fibers when the relationship of these axons and the α-MSH-IR neurons were 
studied at ultrastructural level. Double-labeling immuno-electron microscopy revealed that 
synaptic associations were frequently observed between the UCN3-IR axons and α-MSH-IR 
perikarya and dendrites. In all cases, the synaptic associations were asymmetric type, 
indicative of the excitatory nature of this synaptic communications.  
Since central administration of both TRH and UCN3 have a similar effect to reduce food 
intake as do activation of POMC neurons [3, 65, 125], we hypothesized that both peptides 
would stimulate POMC neurons and that their co-administration would have an additive 
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effect. Therefore, based on the presented morphological data, our laboratory performed patch 
clamp electrophysiological studies to determine the role of TRH and UCN3 in the regulation 
of the POMC neurons. The data of these experiments showed that the two peptides had 
opposite effects on the POMC neurons. As expected, UCN3 markedly depolarized the POMC 
neurons by acting on CRF type 2 receptor (CRFR2) and increased the spontaneous firing 
frequency of these cells demonstrating that UCN3 activates the POMC neurons.  
In contrast, TRH treatment caused hyperpolarization of POMC neurons and decreased the 
firing frequency of these cells. The effect of TRH on the membrane potential of POMC 
neurons was prevented by tetrodotoxin, a compound that blocks the synaptic inputs, 
suggesting that the inhibitory effect of TRH on the POMC neurons is indirect. Simultaneous 
administration of TRH with UCN3 completely prevented the effects of UCN3 on the 
membrane potential and the firing of POMC neurons. The effect of TRH on the UCN3 
induced depolarization was preserved even in the presence of tetrodotoxin, indicating that 
TRH can act directly on POMC neurons; and antagonizes UCN3-induced stimulation rather 
than having an additive effect. 
The antagonistic effect of the two peptides was surprising as TRH has stimulatory effects on 
many cell types [126-128]. However, Ballerini et al. [129] observed a similar phenomenon in 
pyramidal cells of the hippocampal CA1 region, showing that TRH has no effect on the 
membrane potential of those cells but prevented the effect of an another transmitter [129]. The 
highly divergent effects of TRH on target neurons may be due to differential expression of the 
two TRH receptors, TRHR1 and 2, in these cell populations. Since specific antagonists of 
TRH receptors are unavailable, the receptor specificity of the TRH effect on POMC neurons 
could not be detected.  
Our data suggest, however, that while UCN3 may inhibit food intake by stimulating POMC 
neurons of the ARC, TRH may prevent or terminate the effect of UCN3. These data are 
especially interesting because the two, anorexigenic peptides are released from the very same 
axon terminals and exerted antagonistic effects on the POMC neurons. So far, the 
physiological importance of this interaction is not yet clear. We hypothesize, however, that the 
differential expression and release of the two peptides enables TRH/UCN3 neurons to exert 
distinct effects on the POMC neurons under different physiological or pathophysiological 
conditions. Further studies using optogenetics may help to understand whether the length, 
pattern or the frequency of the firing of TRH/UCN3 neurons differentially alter the release of 
the two peptides, and whether the two peptides are released simultaneously from the axons or 
independently or sequentially of each other. In the latter case, TRH might terminate the UCN3 
induced excitation of POMC neurons.  
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Since stress increases the synthesis of UCN3 in perifornical neurons [25] and causes anorexia 
via activation of the POMC neurons of the ARC [25], based on our current data, we raise the 
possibility that TRH/UCN3 neurons of the perifornical area/BNST region mediate the effects 
of stress on POMC neurons. However, further studies will be necessary to understand the 
importance of this pathway in the stress-induced activation of the POMC neurons, and to 
identify the pathways activating the TRH/UCN3 neurons during stress. 
 Relationship between TRH-IR axons and histaminergic neurons in the subnuclei V.5
of the TMN 
Histamine producing neurons are located in the posterior hypothalamus, in the TMN [108]. 
Histamine serves as a neurotransmitter in the brain and plays important role in the regulation 
of body weight. Numerous previous studies confirmed that the central administration of 
histamine can reduce food intake [70, 130, 131]. The mechanisms by which histaminergic 
neurons are integrated into the central mechanisms for weight regulation are not completely 
known, but the observation that the anorexic effects of TRH on food intake can be attenuated 
by preventing the synthesis of histamine raises the possibility that non-hypophysitropic TRH-
synthesizing neurons may comprise at least one of the feeding related inputs of the 
histaminergic neurons. We demonstrated that TRH-IR axons densely innervate all five 
subdivisions of the TMN and establish numerous, close appositions with histaminergic 
neurons in each subdivision. 
Ultrastructural analysis showed that TRH-IR axons frequently establish synaptic associations 
with both the perikaryon and dendrites of histamine-IR neurons. While both symmetric and 
asymmetric type synapses were observed, the number of asymmetric type synapses was 
almost 3 times higher than the number of symmetric type specializations. Since, the 
asymmetric type synaptic association is considered a characteristic feature of the excitatory 
neuronal connections [132] the data suggest that TRH exerts primarily stimulatory effect on 
the histaminergic neurons. This is in agreement with the earlier findings showing that, central 
administration of TRH increases histamine concentration in the TMN [133] and has a 
depolarizing effect on histaminergic neurons [134]. TRH can exert its effects via TRHR1 or 
TRHR2 receptors or both of them [135]. Although single cell PCR has demonstrated both 
types of receptors in some of the histaminergic neurons [134], but using 
immunocytochemistry, only TRHR2 has been visualized [133]. Due to the lack of selective 
TRHR antagonists, functional studies could not be performed to determine the receptor type 
mediating the effects of TRH on the histaminergic neurons. 
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How symmetric type TRH synapses contribute to the regulation of histaminergic neurons 
requires further study, but raises the possibility that the origin of TRH neurons that innervate 
the TMN neurons is diverse.  
Juxtaposition of TRH-IR axons to histamine-IR neurons was observed in all subnuclei of the 
TMN, but the densest innervation pattern was observed in the dorsomedially located E4 
subnucleus. Here, approximately four times more TRH-IR axons were observed on the surface 
of the innervated histamine-IR neurons than any other TMN subnucleus. The physiological 
significance for this innervation pattern is currently unclear, as very little is known about the 
functional differences of the various TMN subnuclei. Early anatomical studies suggest that all 
TMN subnuclei have similar projection patterns. Namely, tract tracing studies showed that 
retrogradely labeled histaminergic neurons were equally observed in all subnuclei after tracer 
injection into the studied projection fields [136] indicating that they may subserve similar 
functions. Restraint stress, insulin-induced hypoglycaemia and foot shock, however, induce 
neuronal activation preferentially in the E4 and E5 TMN subnuclei [137] suggesting 
functional heterogenity. Furthermore, Mahia et al. [138] demonstrated that electrolytic lesions 
of the TMN subnuclei have differential effects on the food intake, such that lesions of the 
ventral E1 and E2 subnuclei result in hyperphagia, whereas similar lesions of E3 and E4 
subnuclei have no effect. Electrolytic lesions not only damage neuronal perikarya, however, 
but also axons of passage. Since the caudal ARC is closely juxtaposed to the E3 and E4 
subnuclei, ablation of the axons emanating from the ARC might have confounded 
interpretation of the data. Further studies using focal injections of TRH into the different 
subnuclei of the TMN, therefore, will be necessary before definitive conclusions can be 
rendered about the preferential role of any of the TMN subnuclei in the mediation of the 
anorexigenic effects of TRH. 
In addition to the effects of TRH on food intake, TRH also participates in the central control of 
thermoregulation through effects independent of elevations in circulating thyroid hormone 
levels. Without affecting circulating T3 levels, intracerebroventricular administration of TRH 
increases rectal temperature and temperature of BAT that can be prevented by pretreatment 
with antibodies to the type 1 TRH receptor [139]. In addition, exposure of the total TRH KO 
mouse to cold results in hypothermia that cannot be fully rescued by restoring thyroid 
hormone levels [140] Since bilateral denervation of the sympathetic nerves innervating BAT 
or the administration of β-adrenergic antagonists markedly attenuate the thermogenic response 
of centrally administered TRH [139], the effects of TRH are presumably mediated through the 
sympathetic innervation of BAT. Activation of histaminergic neurons also increases 
thermogenesis through activation of the sympathetic innervation to BAT [70]. Thus, it is 
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possible that the TRH innervation of histaminergic neurons in the TMN may also mediate the 
thermogenic effect of this peptide on BAT. 
Histaminergic neurons in the TMN may also mediate the effect of TRH on wakefulness. Both 
TRH and histamine are known to increase arousal [141, 142], and inhibition of histamine 
synthesis by α-FMH blocks the effect of the TRH analog, montirelin, to induce arousal, 
suggesting that the effect is mediated by histaminergic neurons. Since wakefulness results in 
c-Fos activation in all TMN subnuclei [143] it is possible that all subnuclei may be involved in 
the mediation of the effects of TRH on arousal. 
Based on the described anatomical connections, we are currently performing tract tracing 
studies to identify the sources of the TRH-IR innervation of the histaminergic neurons. After 
identification of the TRH cell populations innervating the histaminergic neurons, we plan to 
perform optogenetic or chemogenetic studies to study the role of these TRH cell populations 
in the regulation of energy homeostasis. 
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VI. New scientific results 
 [C1-C5] Thesis I VI.1
The ultrastructural localization of the elements of the nitric oxide transmitter system in the 
parvocellular part of the PVN indicate that NO is utilized as both anterograde and 
retrograde neurotransmitter in this brain region.  
The nNOS and the sGC has both pre- and postsynaptic localization in the parvocellular part of 
the PVN indicating that the NO may serve as both anterograde and retrograde transmitter in 
this brain region.  
 [C1-C5] Thesis II  VI.2
NO and the endocannabinoid systems are associated to the same synapses of the 
parvocellular neurons of the PVN. 
nNOS is associated to the postsynaptic side of a population of the synapses formed by CB1-IR 
terminals on the parvocellular neurons. These data indicate that the NO and the 
endocannabinoid systems may interact in the regulation of presynaptic terminals in the 
parvocellular part of the PVN. 
 [C1-C5] Thesis III  VI.3
The endocannabinoid and the NO systems of the PVN are involved in the mediation of the 
NPY induced regulation of energy homeostasis  
Both transmitter systems have critical, but different role in the mediation of the effects of NPY 
on the energy homeostasis. While the NO system of the PVN mediates the effects of NPY on 
the food intake, the endocannabinoid system of this nucleus is involved in the mediation of the 
NPY induced regulation of energy expenditure. Furthermore, data of our group indicates that 
different neuronal circuits of the PVN are involved in the regulation of food intake, energy 
expenditure and locomotor activity by NPY. 
 [J1] Thesis IV  VI.4
MCT8 thyroid hormone transporter presents in the axon terminals of the hypophysiotropic 
TRH neurons. 
MCT8 is present in the hypophysiotropic axon terminals in the external zone of the ME. 
Furthermore, specifically the axon terminals of the hypophysiotropic TRH neurons also 
contain this thyroid hormone transporter. Based on this finding, a novel concept of the thyroid 
hormone feedback regulation of the hypophysiotropic TRH axons was established. 
DOI:10.15774/PPKE.ITK.2018.001
70 
 
 [J2] Thesis V VI.5
The TRH/UCN3 neurons of the perifornical area/BNST region innervate the feeding 
related neuronal groups of the ARC. 
The axons of the TRH/UCN3 neurons juxtapose to only the minority of the NPY neurons of 
the ARC, but contacts more than half of the α-MSH neurons of the nucleus. At ultrastructural 
level, the TRH/UCN3 axons establish asymmetric type synaptic specializations with the α-
MSH neurons.  
 [J3] Thesis VI  VI.6
TRH-containing axons innervate the histaminergic neurons in all subnuclei of the TMN. 
TRH-IR axons densely innervate the histaminergic neurons in all subnuclei of the TMN, and 
establish synaptic specializations on the surface of these neurons. The majority of the synaptic 
contacts were found to be asymmetric type, but symmetric synapses were also found between 
the two systems.  
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